identification of genes encoding hypothetical proteins in ... · these genes, we generated 1161...

©FUNPEC-RP www.funpecrp.com.brGenetics and Molecular Research 10 (3): 1589-1630 (2011)

Identification of genes encoding hypothetical proteins in open-reading frame expressed sequence tags from mammalian stages of Trypanosoma cruzi

C. Martins1, J.L. Reis-Cunha2, M.N. Silva1, E.G. Pereira1, G.J. Pappas Jr.3,4, D.C. Bartholomeu2 and B. Zingales1

1Departamento de Bioquímica, Instituto de Química, Universidade de São Paulo, São Paulo, SP, Brasil2Departamento de Parasitologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brasil3Embrapa Recursos Genéticos e Biotecnologia, Brasília, DF, Brasil4Universidade Católica de Brasília, Brasília, DF, Brasil

Corresponding author: B. ZingalesE-mail: [email protected]

Genet. Mol. Res. 10 (3): 1589-1630 (2011)Received November 30, 2010Accepted January 21, 2011Published August 5, 2011DOI http://dx.doi.org/10.4238/vol10-3gmr1140

ABSTRACT. Approximately 50% of the predicted protein-coding genes of the Trypanosoma cruzi CL Brener strain are annotated as hypothetical or conserved hypothetical proteins. To further characterize these genes, we generated 1161 open-reading frame expressed sequence tags (ORESTES) from the mammalian stages of the VL10 human strain. Sequence clustering resulted in 435 clusters, consisting of 339 singletons and 96 contigs. Significant matches to the T. cruzi predicted gene database were found for ~94% contigs and ~69% singletons. These included genes encoding surface proteins, known to be intensely expressed in the parasite mammalian stages and implicated in host cell invasion and/or immune evasion mechanisms. Among 151 contigs and singletons with similarity to predicted hypothetical protein-

1590


C. Martins et al.

coding genes and conserved hypothetical protein-coding genes, 83% showed no match with T. cruzi EST and/or proteome databases. These ORESTES are the first experimental evidence that the corresponding genes are in fact transcribed. Sequences with no significant match were searched against several T. cruzi and National Center for Biotechnology Information non-redundant sequence databases. The ORESTES analysis indicated that 124 predicted conserved hypothetical protein-coding genes and 27 predicted hypothetical protein-coding genes annotated in the CL Brener genome are transcribed in the VL10 mammalian stages. Six ORESTES annotated as hypothetical protein-coding genes showing no match to EST and/or proteome databases were confirmed by Northern blot in VL10. The generation of this set of ORESTES complements the T. cruzi genome annotation and suggests new stage-regulated genes encoding hypothetical proteins.

Key words: Trypanosoma cruzi; Mammalian stages; ORESTES; Hypothetical protein-coding genes; Transcription

INTRODUCTION

Trypanosoma cruzi is the etiological agent of Chagas disease, which afflicts 8 to 10 million people in Latin America. As a consequence of the intense migration of Latin-Americans from endemic regions, Chagas disease has now become a public health concern in several countries, such as the United States, Canada, Spain, and Japan, among others.

T. cruzi is a digenetic protozoan of the order Kinetoplastida, able to infect a great variety of mammalian species and is transmitted by insects of the family Triatominae. Chagas disease has different clinical presentations. Approximately 70% of seropositive individuals are asymptomatic (indeterminate form), whereas 30% develop serious cardiac, digestive and/or neurological diseases. Each year, 2-3% of the asymptomatic individuals will progress to the above-mentioned symptomatic manifestations (Pinto Dias, 2006). The outcome of infection in a particular individual is the result of a set of complex interactions among the genetic make-up of the parasite, the host immunogenetic background and environmental factors (reviewed by Campbell et al., 2004; Macedo et al., 2004).

The biological, biochemical and genetic diversity of T. cruzi strains has long been recog-nized along with their eco-epidemiological complexity, which have been reviewed extensively elsewhere (Macedo and Pena, 1998; Campbell et al., 2004; Miles et al., 2009). Although it has been initially proposed that the major genetic variability of T. cruzi re sults from clonal evolu-tion, increasing evidence indicates that hybridization events must have contributed to the present population structure (Tomazi et al., 2009). Numerous approaches have been used to define the number of relevant T. cruzi groups, which have received different designations (reviewed by Zingales et al., 2009). In an effort to unify the nomenclature, there was agreement on an updated system in 2009 and a consensus was reached that T. cruzi strains should be referred to by six dis-crete typing units (DTUs) named T. cruzi I-VI (TcI-VI) (Zingales et al., 2009). A DTU is defined as ‘‘sets of stocks that are genetically more related to each other than to any other stock and that are identifiable by common genetic, molecular, or immunological markers’’ (Tibayrenc, 1998).

1591


Transcriptome of Trypanosoma cruzi mammalian stages

The T. cruzi genome sequencing project was completed in 2005, focusing on the hybrid CL Brener (TcVI) strain (El-Sayed et al., 2005). Assembly parameters were adjusted to contend with the high allelic variation, and partial sequencing of the Esmeraldo cl3 strain from the progenitor TcII DTU allowed the definition of two haplotypes of CL Brener, which were named Esmeraldo and non-Esmeraldo (El-Sayed et al., 2005). An updated version of the CL Brener nuclear genome architecture using the genome project data and synteny information with the Trypanosoma brucei genome has been presented (Weatherly et al., 2009). Over 50% of the CL Brener genome is represented by repetitive sequences, consist-ing mostly of large gene families of surface proteins, retrotransposons, subtelomeric repeats (El-Sayed et al., 2005), and the 195-bp satellite DNA (Martins et al., 2008). In the origi-nal report, it was concluded that the CL Brener haploid genome contains ~12,000 protein-coding genes (El-Sayed et al., 2005). However, the number of protein-coding sequences and pseudogenes may be twice the previous estimate (Arner et al., 2007). Putative function could be assigned to 50.8% of the predicted protein-coding genes on the basis of significant similarity to previously characterized proteins or known functional domains (El-Sayed et al., 2005). This means that for around 6000 proteins the function is unknown and further characterization is needed.

The assessment of T. cruzi gene expression was initially obtained by large-scale single pass sequencing of cDNA clones to generate expressed sequence tags (ESTs), mainly of the epi-mastigote stage encountered in the gut of the triatomid insect vector (reviewed by Aguero et al., 2006). More recently, whole genome oligonucleotide microarrays were employed to determine the extent to which T. cruzi regulates mRNA relative abundances over the course of its com-plete life-cycle (Minning et al., 2009). In parallel, several proteomic studies have been carried out to validate or discover novel gene products (Atwood III et al., 2005; Ferella et al., 2008).

Most of the genome, transcriptome and proteomic data have been obtained for the CL Brener strain (TcVI), a clone of the CL strain isolated from the vector Triatoma infestans in south Brazil (Zingales et al., 1997). On the other hand, TcII DTU is the primary cause of severe acute and chronic Chagas disease in southeast and central Brazil (Carranza et al., 2009; Miles et al., 2009). Due to the high genetic diversity of T. cruzi strains, transcriptome and proteomic information from human-derived isolates will contribute to the understanding of pathogenic features of this parasite.

Most ESTs (200-500 nt) correspond to the 5' or 3' end of cDNAs, and may there-fore be derived from untranslated regions of the transcripts. In contrast, open-reading frame (ORF) EST methodology, called ORESTES (Dias et al., 1997), is an alternative approach that allows the generation of sequences preferentially from the transcript central portion, presumably the most informative region of the gene. The basis of the ORESTES approach is to generate short cDNA templates by reverse transcription (RT) and polymerase chain reac-tion (PCR) using arbitrarily selected, non-degenerate primers under low-stringency condi-tions (Dias et al., 1997). Because the position of the amplified fragments within transcripts is highly ordered, a high percentage of fragments encompassing the central portion of the cDNAs is obtained (Dias et al., 1997, 2000). Besides preferential targeting of ORF regions, ORESTES strategy results in a partial equalization of cDNA species, similar to normaliza-tion, which in turn facilitates the discovery of low-abundance transcripts (Dias et al., 2000). Such methodology has been successfully used in the definition of the human transcriptome (Dias et al., 2000; Camargo et al., 2001).

1592


C. Martins et al.

In this study, we undertook a novel T. cruzi transcriptome survey employing the ORESTES approach in order to analyze gene expression in the mammalian stages of the TcII VL10 strain, isolated from a patient in the chronic phase of Chagas disease.

MATERIAL AND METHODS

T. cruzi VL10 strain and cultivation

The VL10 strain was isolated from a 15-year-old female patient in Minas Gerais, Brazil. The patient presented a normal electrocardiogram and normal chest X-rays and was considered to be asymptomatic (indeterminate form). The VL10 strain was genotyped as belonging to TcII DTU (Baptista et al., 2006). Trypomastigote and amastigote forms were obtained from the su-pernatant of monolayers of Simian LLC-MK2 cells on the 7th day post-infection, as described previously (Zingales et al., 1997). Epimastigote forms of CL Brener (TcVI DTU) and VL10 strains were cultured in liver infusion-tryptose (LIT) medium with 10% FBS, at 28°C.

cDNA template preparation and DNA sequencing

PolyA+ RNA was prepared from 109 parasites using the µMACS kit (Miltenyi Bio-tec, Auburn, CA, USA) according to manufacturer instructions. RNA samples were treated with DNase I (10 U/50 µg RNA), and the absence of contaminating genomic DNA was confirmed by PCR using primers for the 195-bp satellite DNA and the LSU RNA gene, as previously described (Martins et al., 2008). RNA integrity was confirmed by means of RT-PCR using primers for the T. cruzi actin 2 (GenBank accession #AF494294) and elongation factor 1 (GenBank accession #L76077) genes. To produce cDNA templates, the ORESTES methodology (Dias et al., 2000) was employed with some modifications. Samples of 10-30 ng purified DNAse-treated mRNA were heated at 65°C for 5 min and then subjected to RT at 37°C for 60 min in the presence of 200 U Superscript II Reverse Transcriptase (Invitrogen) and 15 pmol randomly selected primers in a final volume of 20 µL. The five primers used for cDNA synthesis and amplification were 18-mers with GC content of 50 to 77% (PS0229, 5'-GAGTAGACTCTGTCCTGG-3'; PS0236, 5'-TGGGAGTCCATGC GTGCC-3'; PS0225, 5'-GTGACCACCAGCTGCTGC-3'; PS0230, 5'-ACCGCAGCG GACAGCGCC-3'; PS0231, 5'-GACAGCAGGACCAAGCCA-3'). After cDNA synthesis, 2 µL of each single-stranded cDNA was PCR amplified using the same primer employed in the RT reaction with the Ready-to-go PCR beads system (GE Healthcare) according to manufacturer instructions. Touchdown PCR with 45 cycles was used after cDNA denatur-ation at 75°C. Annealing temperatures varied from 52° to 45°C (with progressive reduc-tions of 1° to 2°C per cycle). The samples were run on 1% low-melting temperature aga-rose gels and stained with ethidium bromide. After electrophoresis, profiles composed of a DNA smear were size selected from the gels and cloned in pGEM-T Easy vector (Promega) according to standard procedures. Plasmid templates were prepared using 96-Plasmid Puri-fication System kits for the Biomek 2000 Automation Workstation (Beckman). Sequencing was carried out using an ABI 377 automated DNA sequencer (Applied Biosystems Inc.). Nucleotide sequences determined here have been deposited in the GenBank database with the accession numbers GW395924-GW397084.

1593



EST processing pipeline

Sequence analysis began with base calling using the phred program (Ewing and Green, 1998). Sequence quality trimming was performed with the lucy program (Chou and Holmes, 2001), and vector masking with the cross match program (Ewing B, unpublished results). The processed sequences were clustered with the CAP3 program (Huang and Madan, 1999), generating the sequence consensi that were used in sequence annotation.

Sequence annotation

Contigs and singletons were searched as a query against the T. cruzi predicted gene database (http://tritrypdb.org/tritrypdb/) using the BLASTN algorithm with low complexity filtering turned off. Matches with a bit score ≥100 were considered to be significant. Sequences with no significant match were searched against the T. cruzi contig database using the same parameters, and those that still did not have a significant match were searched against the T. cruzi reads database. Sequences with no signifi-cant similarity with any of the three databases were searched against the non-redundant nucleotide and protein sequences at NCBI using BLASTN and BLASTX, respectively. All 435 consensi were also searched against EST/cDNA sequences and proteome T. cru-zi databases (http://www.tritrypdb.org) and pfam domains (http://pfam.sanger.ac.uk/) (Supplementary Material S1 - Annotation - ORESTES).

Southern blotting

Total parasite DNA was obtained as described (Macedo et al., 1992). DNA preparations (10 µg) were digested with PstI restriction enzymes (New England Biolabs), run on 0.8% aga-rose gels, and blotted onto nylon membranes (Hybond-N, Amersham Pharmacia) using standard protocols. DNA probes were labeled with [a-32P]-dATP with the Random Primer DNA Label-ing kit (Invitrogen). Probes were hybridized at 60°C in 0.1% Ficoll, 0.05% PVP, 1 mM EDTA, 3X SSC, 0.1% SDS and 100 µg/mL salmon sperm DNA. Blots were washed to a final stringency of 1X SSC, 0.1% SDS at 60°C. The radioactive images were recorded on X-ray films.

RNA blotting

Total parasite was RNA extracted with the TRIzol reagent according to manufacturer instructions, DNase-treated and separated on formaldehyde-containing 1% agarose gels in MOPS buffer according to standard procedures and blotted onto nylon membranes (Hybond-N, Amersham Pharmacia). DNA probes were labeled as above. Hybridization was carried out in 5X SSPE, 50% formamide, 5X Denhardt, 0.5% SDS at 42°C, overnight. Blots were washed to final stringency of 1X SSPE, 0.1% SDS at 42°C, and exposed to X-ray films.

RESULTS AND DISCUSSION

ORESTES were obtained from DNase-treated PolyA+ RNA samples of trypomasti-gote and amastigote forms (3:1 proportion) of the human VL10 strain, recovered in the su-

1594


C. Martins et al.

pernatant of LLC-MK2 monolayers. Amastigotes were obtained mostly by the premature lysis of infected cells or from the extracellular differentiation of trypomastigotes. Like trypomasti-gotes, extracellular amastigotes are capable of invading both professional and non-professional phagocytes and sustain the parasite’s life cycle (Fernandes et al., 2006 and cited references).

No amplification of T. cruzi abundant genomic sequences, the 195-bp satellite DNA (Martins et al., 2008) and the LSU RNA genes, was observed in the RNA samples, ruling out the presence of contaminating genomic DNA (data not shown). The integrity of the mRNA samples was confirmed by RT-PCR using primers for T. cruzi actin 2 and elongation factor 1 genes (data not shown). Synthesis and amplification of the cDNA templates were obtained with five 18-mer primers. The criterion for primer selection was GC content ≥50%, and no specific sequence constraints were imposed (Dias et al., 2000). After cDNA electrophoresis, profiles composed of a DNA smear between 400 and 900 bp were excised from the gels, cloned in pGEM-T Easy vector and sequenced.

In total 1522 ORESTES were generated, of which 68% were obtained with PS0225 and PS0230 primers. Post-processing to exclude primer and vector sequences, as well as low-quality bases, resulted in 1161 ORESTES with an average phred-generated base-quality value of 20.3 (i.e., 99% base call accuracy) and average size of 500 nt. This size is adequate for transcript identification, since the average size of a T. cruzi coding DNA sequence (CDS) is 1513 bp (El-Sayed et al., 2005). We determined that the ORESTES G+C content was 52.7%, in agreement with the reported CDS G+C content of 53.4%, which is higher than the average G+C content of inter-coding regions (47%) (El-Sayed et al., 2005). Sequence clustering was performed by the CAP3 program, resulting in 479 clusters, which represented 32.4% of the accepted sequences and indicated a high redundancy level of the library.

Of the 479 clusters, 44 represented contaminant sequences, mainly derived from Ma-cacca mulatta (from the LLC-MK2 cell monolayers), and were excluded from the analysis. Of the remaining 435 consensi, 96 (22.1%) contained multiple reads (contigs) and 339 (77.9%) contained only one ORESTES (singletons) (Table 1). The 435 clusters were searched as query against the following T. cruzi databases (http://tritrypdb.org/tritrypdb/): predicted gene con-tigs, individual reads, EST/cDNA sequences and proteome as described in Material and Meth-ods. Sequences with no significant similarity with T. cruzi databases were searched against the non-redundant nucleotide and protein sequences at NCBI using BLASTN and BLASTX, respectively. All 435 consensi were also searched for pfam domains (Supplementary Material S2 - Pfam - ORESTES).

Description Number Percentage

ORESTES contigs 96 100.0 Similarity to Trypanosoma cruzi genes 90 93.7 No similarity to coding sequences, but similarity to T. cruzi contigs 2 2.1 No match with any database 4 4.2ORESTES singletons 339 100.0 Similarity to T. cruzi genes 234 69.0 No similarity to coding sequences, but similarity to T. cruzi contig database 5 1.5 No match with any database 100 29.5

Table 1. ORESTES contig and singleton BLAST matches to nucleotide and protein databases.

1595



Table 1 summarizes the similarity search results. Around 94% contigs and 69% sin-gletons displayed significant matches with T. cruzi predicted genes. Considering the reference CL Brener genome haplotypic distribution and classification into Esmeraldo- or non-Esmeral-do-like alleles (El-Sayed et al., 2005), it was possible to identify that 87.5% contigs and 95.6% singletons had higher identity with Esmeraldo-like alleles (Supplementary Material S1 - An-notation - ORESTES). This confirms that VL10 and Esmeraldo strains are closely related, both belonging to the TcII DTU (Zingales et al., 2009). A total of 2 contigs and 5 singletons corresponded to non-annotated regions of T. cruzi contigs. One of these sequences matched to a maxicircle sequence (mitochondrial genome was not part of the annotated genome da-taset) (Westenberger et al., 2006); two sequences were part of missing portions of annotated partial genes, and four sequences were likely untranslated sequences since they were derived from inter-coding regions (Supplementary Material S1 - Annotation - ORESTES). Around 4.2% contigs and 29.5% singletons resulted in no matches against either the T. cruzi databases (coding-sequences, contigs or reads) or the non-redundant Genbank protein database. Part of these ORESTES may have been derived from cloning artifacts.

Significant information obtained from highly populated clusters is that the relative levels of gene expression can provide a snapshot of the physiological state of the cells. In this direction, the list of the 15 most populated ORESTES clusters and their best blastn hit against T. cruzi genes and contigs is reported in Table 2. Of these clusters, 40% represented hypothetical conserved proteins. The putative dispersed gene family 1 (DGF-1) protein was found in two clusters. DGF-1 proteins are encoded by ~500 genes (El-Sayed et al., 2005) and are localized in the parasite cell membrane. One of the DGF-1 members (DGF1.2) is more abundant in the amastigote stage than in trypomastigotes and epimastigotes, and its expression is developmentally regulated (Lander et al., 2010). Interestingly, transcripts from DGF-1 have not been previously reported in T. cruzi EST databases (Table 2). This was also the case with the sequences of 13 of the 15 most populated ORESTES clusters (Table 2), indicating that the ORESTES strategy is an alternative methodology to identify novel gene transcripts.

Contig ORESTES Best BLASTN hit against Annotation Best BLASTN hit (No.) (count) T. cruzi genes and contigs against T. cruzi ESTs

16 6 Tc00.1047053508179.70 GPR1/FUN34/yaaH family, putative Null11 8 Tc00.1047053507653.40 Dispersed gene family protein 1 (DGF-1), putative Null90 8 Tc00.1047053509865.9 Retrotransposon hot spot (RHS) protein, putative Null89 8 Tc00.1047053507479.29 NUP-1 protein (pseudogene), putative Null20 9 Tc00.1047053510431.190 Hypothetical protein, conserved Null64 10 Tc00.1047053507083.109 Hypothetical protein, conserved Null62 12 Tc00.1047053509157.170 Trans-sialidase, putative Null54 14 Tc00.1047053507099.80 ABC transporter, putative Null95 14 Tc00.1047053506481.30 Hypothetical protein, conserved Null35 15 Tc00.1047053399389.10 Hypothetical protein, conserved Null 6 22 Tc00.1047053511727.290 RNA binding protein, putative TENU4719 epimastigote normalized cDNA library (5' mRNA sequence)50 25 Tc00.1047053508367.50 Hypothetical protein, conserved (pseudogene) TENU1365 epimastigote normalized cDNA library (3' mRNA sequence)23 30 Tc00.1047053504929.5 Hypothetical protein, conserved Null83 32 Tc00.1047053510275.130 Dispersed gene family protein 1 (DGF-1), putative Null42 89 Null Not identified Null

Table 2. Annotation of the most populated ORESTES clusters obtained after selecting the best BLASTN hit against Trypanosoma cruzi databases.

1596


C. Martins et al.

Analysis of the best BLASTX hits against T. cruzi proteome databases indicated that of these 15 ORESTES clusters, only the proteins related to contig89 (putative NUP-1 protein, pseudogene) and contig90 (putative retrotransposon hot spot (RHS) protein) have been depos-ited in this database (Supplementary Material S1 - Annotation - ORESTES). Coincidentally, RHS protein was characterized in amastigote, trypomastigote and metacyclic infective stages, and the nuclear envelope protein NUP-1, in the metacyclic insect stage. For the highly popu-lated contig42, no match was found with any database (Table 2).

Next we analyzed the ORESTES matching T. cruzi predicted genes (Figure 1). The ma-jority of the contigs (55%) and large proportion of singletons (43%) were derived from known coding sequences previously reported in T. cruzi and/or other organisms, and annotated here as predicted protein-coding genes. These included genes encoding surface proteins such as the trans-sialidase/gp85 superfamily, mucin-associated surface protein (MASP), mucin TcMUCII, DGF-1, and surface protease GP63 (Supplementary Material S1 - Annotation - ORESTES), all known to be intensely expressed in the mammalian stages of the parasite (Frasch, 2000; Grandgenett et al., 2000; Buscaglia et al., 2004; Bartholomeu et al., 2009; Lander et al., 2010).

Figure 1. Distribution of the ORESTES contigs (N = 90; Panel A) and singletons (N = 234; Panel B) among classes of Trypanosoma cruzi predicted genes.

1597



In comparison with Leishmania major and T. brucei genomes, T. cruzi shows a remarkable expansion of these gene families, corresponding to approximately 20% of the total protein-coding genes. Some of these families are T. cruzi-specific such as MASP, mu-cin TcMUC and DGF-1, while others are much more expanded in T. cruzi compared with T. brucei and/or L. major, such as gp85/trans-sialidase and GP63 (El-Sayed et al., 2005 and cited references). Each of the three parasite species evolved a specific surface coat adapted for survival and proliferation in the different niches they occupy in the mammalian host. Unlike T. brucei, which is exclusively extracellular, and L. major, which infects macro-phages, T. cruzi has the ability to infect and proliferate within a large variety of host cell types. It has been demonstrated that several of these T. cruzi surface proteins are glycosyl-ated and mediate host cell attachment and invasion and/or intracellular replication (Acosta-Serrano et al., 2001; Kulkarni et al., 2009; Albertti et al., 2010). Additionally, some of these molecules are implicated in immune evasion mechanisms (Pereira-Chioccola et al., 2000; Pitcovsky et al., 2002; Gao et al., 2002).

We have also found that a small proportion of the contigs and singletons match retroelements, related to the modeling of T. cruzi genome (El-Sayed et al., 2005), the transcribed repetitive 195-bp satellite DNA sequence (Martins et al., 2008) and ribosomal RNA genes.

In addition to T. cruzi genes experimentally characterized, we also identified a con-siderable number of contigs (28%) and a large proportion of singletons (42%) corresponding to genes matching hypothetical proteins also identified in other organisms, but with unknown function (annotated as predicted conserved hypothetical protein-coding genes) (Figure 1). Of particular interest are a number of contigs (7%) and singletons (9%) matching hypothetical proteins, which are putatively T. cruzi-specific genes.

Aiming to investigate the genomic organization of some ORESTES sequences, Southern blots of total DNA of epimastigote forms of CL Brener and VL10 strains were digested with PstI and hybridized with five probes: three ORESTES that showed no match with any database (one member of contig42, contig59 and the singleton TCA236-IQ001_E12_.B_10.ab1); one member of contig83 (DGF-1; GenBank accession #GW396523) and contig23 (hypothetical protein, conserved; GenBank accession #GW396011) (Figure 2). No hybridization signal was obtained for the highly populated contig42 probe (Table 2), confirm-ing that these sequences are artifacts. On the other hand, the probes of the two other no-match ORESTES (contig59 and singleton TCA236-IQ001_E12_.B_10.ab1) identified DNA bands in the two strains (Figure 2B and C). Some differences in the organization of DGF-1 in the genome of CL Brener and VL10 could be detected (Figure 2D). In contrast, the same hybrid-ization pattern in the two strains was observed for the conserved hypothetical protein-coding gene of contig23 (Figure 2E).

Among the ORESTES contigs and singletons with similarity to predicted conserved hypothetical protein-coding genes and predicted hypothetical protein-coding genes (total 151), 82.8% (125/151) showed no matches against T. cruzi EST and proteome databases (Sup-plementary Material S1 - Annotation - ORESTES). These ORESTES sequences are the first experimental evidence that the corresponding genes are in fact transcribed. Those matching hypothetical protein-coding genes, which showed no similarity to EST and proteome data (12 in total), deserve further investigation since they are likely to be T. cruzi-specific and ex-pressed in the mammalian infective stages.

1598


C. Martins et al.

To further characterize the 151 contigs and singletons matching hypothetical and con-served hypothetical proteins, the corresponding proteins were searched for conserved domains against the Pfam database (http://pfam.sanger.ac.uk/), with a cutoff e-value of 10-5 (Supple-mentary Material S2 - Pfam - ORESTES). The data are summarized in Table 3. Considering the 31 ORESTES contigs, Pfam domains were identified in 7 of 25 conserved hypothetical proteins and in 1 of 6 hypothetical proteins. Regarding the 120 singletons, Pfam domains were identified in 19 of 99 conserved hypothetical proteins and in 2 of 21 hypothetical proteins (Table 3). Additionally, conserved protein domains could be recognized in 1 of the 6 contigs and 2 of the 14 singletons annotated as hypothetical protein-coding genes and which showed no match against EST and proteome databases (Table 3).

Figure 2. Genomic organization of ORESTES. Southern blot of total DNA of CL Brener (CL) and VL10 (VL) strains digested with PstI. A. Ethidium bromide-stained gel and hybridizations with 32P-labeled probes; B. contig59 (no match); C. singleton (TCA236-IQ001_E12_.B_10.ab1, no match); D. contig83 (GenBank accession #GW396523); E. contig23 (GenBank accession #GW396011). Molecular mass markers are indicated in kb.

Description Total No match with EST and proteome databases

Number Pfam domains Number Pfam domains

Contigs Conserved hypothetical proteins 25 7 22 7 Hypothetical proteins 6 1 6 1Singletons Conserved hypothetical proteins 99 19 83 18 Hypothetical proteins 21 2 14 2

Table 3. Pfam domains of conserved hypothetical proteins and hypothetical proteins of ORESTES contigs and singletons.

1599



In our analysis, we found several ORESTES annotated as hypothetical protein-coding genes that showed no match against EST and proteome databases. Since, in prin-ciple, these genes could be T. cruzi-specific, we decided to confirm the transcript abun-dance of some of these genes by means of Northern blot assays with DNase-treated total RNA of trypomastigote + amastigote forms of the VL10 strain. Because most of T. cruzi ESTs were obtained from CL Brener epimastigotes (reviewed by Aguero et al., 2006), RNA blots of this parasite stage were also included in the analysis (Figure 3). The blots were hybridized with six labeled ORESTES probes. Two probes corresponded to one member of contig03 (GenBank accession #GW395938) and one member of contig25 (GenBank accession #GW396121), and the other four probes to singletons (GenBank accession #GW396611, #GW396648, #GW396850, and #GW396862) (Figure 3). Tran-scripts could be detected in the mammalian forms of VL10 for all six probes, corrobo-rating the ORESTES data indicating that these genes are transcribed. Only the probe derived from contig25 also identified transcripts in CL Brener epimastigotes (Figure 3, panel H). At least three strong hybridization bands were detected by one singleton probe (GenBank accession #GW396862) (Figure 3, panel G). We verified that the hypothetical protein-coding gene, which was the best hit for this singleton matched six other hypo-thetical protein-coding genes (e-value ranging from 10-32 to 10-146) with coding regions varying in length from 585 to 1140 bp. Some of these genes were located at contig ends, and therefore, the size of their corresponding transcripts could not be estimated based on the genome data. Therefore, the various hybridization bands could be originated by cross-hybridization of the probe with these related sequences. For all the other probes, the transcript sizes were compatible with the length of the CDS plus flanking sequences, most probably untranslated regions.

Figure 3. Transcription of hypothetical protein-coding genes. Blots of DNase-treated total RNA of CL Brener epimastigotes (CL) and VL10 trypomastigote + amastigote forms (VL). A. Ethidium bromide-stained agarose gel. The blots were hybridized with 32P-labeled probes; B. Actin 2 housekeeping gene; C. singleton (GenBank accession #GW396611); D. singleton (GenBank accession #GW396648); E. singleton (GenBank accession #GW396850); F. contig03 (GenBank accession #GW395938); G. singleton (GenBank accession #GW396862); H. contig25 (GenBank accession #GW396121). The estimated sizes (in kb) of the transcripts are indicated on the right side of the panels.

1600


C. Martins et al.

The data presented in Figure 3 indicating that five ORESTES probes of hypothetical protein-coding genes recognized RNA transcripts only in the VL10 mammalian stages strongly suggest that the level of expression of these genes is developmentally regulated. In fact, dif-ferential mRNA levels conferring stage-regulated gene expression have been detected on T. cruzi microarrays (Minning et al., 2009) and in several other studies (reviewed by Teixeira and Da Rocha, 2003). On the other hand, the differential hybridization between the CL Brener (TcVI) and VL10 (TcII) strains could be related to genetic differences between the two T. cruzi DTUs (Miles et al., 2009; Zingales et al., 2009).

In conclusion, the ORESTES analysis led to the verification that 124 predicted con-served hypothetical protein-coding genes and 27 predicted hypothetical protein-coding genes annotated in the CL Brener genome are transcribed in the mammalian stages of the VL10 strain. The generation of this small set of ORESTES helps to complement the T. cruzi genome annotation, since the detection of missing portions of genes belonging to the contigs derived from the non-annotated dataset has been possible. The verification that some genes annotated as coding for hypothetical proteins are in fact transcribed will stimulate the characterization of the corresponding proteins that could not be identified by the current proteomic methods due to their low levels or physical properties. This can contribute to a better understanding of the parasite biology and pathogenicity since these are a priori T. cruzi-specific genes. At the same time, this approach provides information on the putative developmental expression of the genes, helping in the use of more assertive strategies for functional studies.

ACKNOWLEDGMENTS

We are greatly indebted to Dr. Emmanuel Dias Neto and Dr. Elida Ojopi for insightful suggestions. Research supported by Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) and Ministério de Ciência e Tecnologia/Conselho Nacional de Desenvolvimento Científico e Tecnológico/Ministério da Saúde (MCT/CNPq/MS-SCTIE-DECIT - Edital de Doenças Negligenciadas) to B. Zingales, UNICEF/UNDP/World Bank WHO for Research and Training in Tropical Diseases, Fundação de Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG), and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) to D.C. Bartholomeu. All authors, except M.N. Silva are recipients of CNPq fellowships.

REFERENCES

Acosta-Serrano A, Almeida IC, Freitas-Junior LH, Yoshida N, et al. (2001). The mucin-like glycoprotein super-family of Trypanosoma cruzi: structure and biological roles. Mol. Biochem. Parasitol. 114: 143-150.

Aguero F, Zheng W, Weatherly DB, Mendes P, et al. (2006). TcruziDB: an integrated, post-genomics community resource for Trypanosoma cruzi. Nucleic Acids Res. 34: D428-D431.

Albertti LA, Macedo AM, Chiari E, Andrews NW, et al. (2010). Role of host lysosomal associated membrane protein (LAMP) in Trypanosoma cruzi invasion and intracellular development. Microb. Infect. 12: 784-789.

Arner E, Kindlund E, Nilsson D, Farzana F, et al. (2007). Database of Trypanosoma cruzi repeated genes: 20,000 additional gene variants. BMC Genom. 8: 391.

Atwood JA III, Weatherly DB, Minning TA, Bundy B, et al. (2005). The Trypanosoma cruzi proteome. Science 309: 473-476.

Baptista CS, Vencio RZ, Abdala S, Carranza JC, et al. (2006). Differential transcription profiles in Trypanosoma cruzi associated with clinical forms of Chagas disease: Maxicircle NADH dehydrogenase subunit 7 gene truncation in asymptomatic patient isolates. Mol. Biochem. Parasitol. 150: 236-248.

Bartholomeu DC, Cerqueira GC, Leao AC, daRocha WD, et al. (2009). Genomic organization and expression profile of

1601



the mucin-associated surface protein (masp) family of the human pathogen Trypanosoma cruzi. Nucleic Acids Res. 37: 3407-3417.

Buscaglia CA, Campo VA, Di Noia JM, Torrecilhas AC, et al. (2004). The surface coat of the mammal-dwelling infective trypomastigote stage of Trypanosoma cruzi is formed by highly diverse immunogenic mucins. J. Biol. Chem. 279: 15860-15869.

Camargo AA, Samaia HP, Dias-Neto E, Simao DF, et al. (2001). The contribution of 700,000 ORF sequence tags to the definition of the human transcriptome. Proc. Natl. Acad. Sci. U. S. A. 98: 12103-12108.

Campbell DA, Westenberger SJ and Sturm NR (2004). The determinants of Chagas disease: connecting parasite and host genetics. Curr. Mol. Med. 4: 549-562.

Carranza JC, Valadares HM, D’Avila DA, Baptista RP, et al. (2009). Trypanosoma cruzi maxicircle heterogeneity in Chagas disease patients from Brazil. Int. J. Parasitol. 39: 963-973.

Chou HH and Holmes MH (2001). DNA sequence quality trimming and vector removal. Bioinformatics. 17: 1093-1104.Dias NE, Caballero OL, Vidigal TH, Pena SD, et al. (1997). Partially degraded DNA of parasitological interest serves as an

adequate template for the production of random amplified polymorphic DNAs (RAPDs). J. Parasitol. 83: 753-755.Dias NE, Correa RG, Verjovski-Almeida S, Briones MR, et al. (2000). Shotgun sequencing of the human transcriptome

with ORF expressed sequence tags. Proc. Natl. Acad. Sci. U. S. A. 97: 3491-3496.El-Sayed NM, Myler PJ, Bartholomeu DC, Nilsson D, et al. (2005). The genome sequence of Trypanosoma cruzi, etiologic

agent of Chagas disease. Science 309: 409-415.Ewing B and Green P (1998). Base-calling of automated sequencer traces using phred. II. Error probabilities. Genome

Res. 8: 186-194.Ferella M, Nilsson D, Darban H, Rodrigues C, et al. (2008). Proteomics in Trypanosoma cruzi - localization of novel

proteins to various organelles. Proteomics 8: 2735-2749.Fernandes AB, Neira I, Ferreira AT and Mortara RA (2006). Cell invasion by Trypanosoma cruzi amastigotes of distinct

infectivities: studies on signaling pathways. Parasitol. Res. 100: 59-68.Frasch AC (2000). Functional diversity in the trans-sialidase and mucin families in Trypanosoma cruzi. Parasitol. Today

16: 282-286.Gao W, Wortis HH and Pereira MA (2002). The Trypanosoma cruzi trans-sialidase is a T cell-independent B cell mitogen

and an inducer of non-specific Ig secretion. Int. Immunol. 14: 299-308.Grandgenett PM, Coughlin BC, Kirchhoff LV and Donelson JE (2000). Differential expression of GP63 genes in

Trypanosoma cruzi. Mol. Biochem. Parasitol. 110: 409-415.Huang X and Madan A (1999). CAP3: A DNA sequence assembly program. Genome Res. 9: 868-877.Kulkarni MM, Olson CL, Engman DM and McGwire BS (2009). Trypanosoma cruzi GP63 proteins undergo stage-specific

differential posttranslational modification and are important for host cell infection. Infect. Immun. 77: 2193-2200.Lander N, Bernal C, Diez N, Anez N, et al. (2010). Localization and developmental regulation of a dispersed gene family

1 protein in Trypanosoma cruzi. Infect. Immun. 78: 231-240.Macedo AM and Pena SD (1998). Genetic variability of Trypanosoma cruzi: Implications for the pathogenesis of Chagas

disease. Parasitol. Today 14: 119-124.Macedo AM, Martins MS, Chiari E and Pena SD (1992). DNA fingerprinting of Trypanosoma cruzi: a new tool for

characterization of strains and clones. Mol. Biochem. Parasitol. 55: 147-153.Macedo AM, Machado CR, Oliveira RP and Pena SD (2004). Trypanosoma cruzi: genetic structure of populations and

relevance of genetic variability to the pathogenesis of Chagas disease. Mem. Inst. Oswaldo Cruz 99: 1-12.Martins C, Baptista CS, Ienne S, Cerqueira GC, et al. (2008). Genomic organization and transcription analysis of the 195-

bp satellite DNA in Trypanosoma cruzi. Mol. Biochem. Parasitol. 160: 60-64.Miles MA, Llewellyn MS, Lewis MD, Yeo M, et al. (2009). The molecular epidemiology and phylogeography of

Trypanosoma cruzi and parallel research on Leishmania: looking back and to the future. Parasitology 136: 1509-1528.

Minning TA, Weatherly DB, Atwood J, III, Orlando R, et al. (2009). The steady-state transcriptome of the four major life-cycle stages of Trypanosoma cruzi. BMC Genom. 10: 370.

Pereira-Chioccola VL, Acosta-Serrano A, Correia dA, I, Ferguson MA, et al. (2000). Mucin-like molecules form a negatively charged coat that protects Trypanosoma cruzi trypomastigotes from killing by human anti-alpha-galactosyl antibodies. J. Cell Sci. 113 (Pt 7): 1299-1307.

Pinto Dias JC (2006). The treatment of Chagas disease (South American trypanosomiasis). Ann. Intern. Med. 144: 772-774.Pitcovsky TA, Buscaglia CA, Mucci J and Campetella O (2002). A functional network of intramolecular cross-reacting

epitopes delays the elicitation of neutralizing antibodies to Trypanosoma cruzi trans-sialidase. J. Infect. Dis. 186: 397-404.

1602


C. Martins et al.

Teixeira SMR and Da Rocha WD (2003). Control of gene expression and genetic manipulation in Trypanosomatidae. Genet. Mol. Res. 2: 148-158.

Tibayrenc M (1998). Genetic epidemiology of parasitic protozoa and other infectious agents: the need for an integrated approach. Int. J. Parasitol. 28: 85-104.

Tomazi L, Kawashita SY, Pereira PM, Zingales B, et al. (2009). Haplotype distribution of five nuclear genes based on network genealogies and Bayesian inference indicates that Trypanosoma cruzi hybrid strains are polyphyletic. Genet. Mol. Res. 8: 458-476.

Weatherly DB, Boehlke C and Tarleton RL (2009). Chromosome level assembly of the hybrid Trypanosoma cruzi genome. BMC Genom. 10: 255.

Westenberger SJ, Cerqueira GC, El-Sayed NM, Zingales B, et al. (2006). Trypanosoma cruzi mitochondrial maxicircles display species- and strain-specific variation and a conserved element in the non-coding region. BMC Genom. 7: 60.

Zingales B, Pereira ME, Almeida KA, Umezawa ES, et al. (1997). Biological parameters and molecular markers of clone CL Brener - the reference organism of the Trypanosoma cruzi genome project. Mem. Inst. Oswaldo Cruz 92: 811-814.

Zingales B, Andrade SG, Briones MR, Campbell DA, et al. (2009). A new consensus for Trypanosoma cruzi intraspecific nomenclature: second revision meeting recommends TcI to TcVI. Mem. Inst. Oswaldo Cruz 104: 1051-1054.

1603



Que

ry

Bes

t bla

stn

hit a

gain

st

Ann

otat

ion

Bes

t bla

stn

hit a

gain

st

EST-

stag

e B

est b

last

x hi

t aga

inst

Pr

oteo

me-

stag

e C

ontig

s R

eads

T.

cru

zi g

enes

and

con

tigs

T.

cru

zi E

STs

T.

cru

zi p

rote

ome

Con

tig1

2350

6.rr

na00

001

RN

A ri

boso

mal

TE

NU

0441

T. c

ruzi

epi

mas

tigot

e Ep

imas

tigot

e N

ull

Nul

l

norm

aliz

ed c

DN

A li

brar

y T.

cru

zi

cDN

A c

lone

4m

9 3'

,

mR

NA

sequ

ence

C

ontig

2 Tc

00.1

0470

5350

6559

.559

A

ntig

enic

pro

tein

, put

ativ

e N

ull

Nul

l N

ull

Nul

lC

ontig

3 Tc

00.1

0470

5350

4039

.110

H

ypot

hetic

al p

rote

in

Nul

l N

ull

Nul

l N

ull

Con

tig4

Tc00

.104

7053

5074

83.4

Po

lyub

iqui

tin (p

seud

ogen

e), p

utat

ive

TcTR

-583

TcT

R T

. cru

zi c

DN

A

Tryp

omas

tigot

e 16

0_Ep

i Ep

imas

tigot

e

clon

e 03

i13

5', m

RN

A se

quen

ceC

ontig

5 Tc

00.1

0470

5350

6265

.100

A

TP-d

epen

dent

RN

A h

elic

ase,

put

ativ

e N

ull

Nul

l N

ull

Nul

lC

ontig

6 Tc

00.1

0470

5351

1727

.290

R

NA

-bin

ding

pro

tein

, put

ativ

e TE

NU

4719

T. c

ruzi

epi

mas

tigot

e Ep

imas

tigot

e N

ull

Nul

l

norm

aliz

ed c

DN

A li

brar

y T.

cru

zi

cDN

A c

lone

40o

22 5

',

mRN

A se

quen

ceC

ontig

7 Tc

00.1

0470

5350

9695

.150

K

ines

in, p

utat

ive

Nul

l N

ull

Nul

l N

ull

Con

tig8

Tc00

.104

7053

5101

01.4

30

40S

ribos

omal

pro

tein

S21

, put

ativ

e am

astc

-406

TcA

M T

. cru

zi cD

NA

A

mas

tigot

e N

ull

Nul

l

clon

e 14

F3 5

', m

RN

A se

quen

ceC

ontig

9 Tc

00.1

0470

5350

6591

.50

Hyp

othe

tical

pro

tein

, con

serv

ed (p

seud

ogen

e)

Nul

l N

ull

Nul

l N

ull

Con

tig10

Tc

00.1

0470

5351

0769

.80

Ank

yrin

repe

at p

rote

in, p

utat

ive

Nul

l N

ull

Nul

l N

ull

Con

tig11

Tc

00.1

0470

5350

7653

.40

Dis

pers

ed g

ene

fam

ily p

rote

in

Nul

l N

ull

Nul

l N

ull

1 (D

GF-

1), p

utat

ive

Con

tig12

Tc

00.1

0470

5350

6401

.210

H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l N

ull

Nul

lC

ontig

13

Tc00

.104

7053

5085

51.3

9 H

exos

e tra

nspo

rter,

puta

tive

amas

tc-4

11 T

cAM

T. c

ruzi

cDN

A

Am

astig

ote

Nul

l N

ull

cl

one

14F8

5',

mR

NA

sequ

ence

Con

tig14

Tc

00.1

0470

5350

4137

.150

H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l N

ull

Nul

lC

ontig

15

Tc00

.104

7053

5036

27.2

0 Pr

otei

n ki

nase

, put

ativ

e N

ull

Nul

l N

ull

Nul

lC

ontig

16

Tc00

.104

7053

5081

79.7

0 G

PR1/

FUN

34/y

aaH

fam

ily, p

utat

ive

Nul

l N

ull

Nul

l N

ull

Con

tig17

Tc

00.1

0470

5350

8865

.4

Prot

ein

phos

phat

ase

2C, p

utat

ive

Nul

l N

ull

Nul

l N

ull

Con

tig18

Tc

00.1

0470

5350

9985

.60

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

Nul

l N

ull

Con

tig19

Tc

00.1

0470

5351

0431

.190

H

ypot

hetic

al p

rote

in

Nul

l N

ull

Nul

l N

ull

Con

tig20

Tc

00.1

0470

5350

6825

.60

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

Nul

l N

ull

Con

tig21

24

358.

rrna

0000

1 R

NA

ribo

som

al

TEN

Q08

45 T

. cru

zi e

pim

astig

ote

Epim

astig

ote

Nul

l N

ull

no

rmal

ized

cD

NA

libr

ary

T. c

ruzi

cD

NA

, mR

NA

sequ

ence

Con

tig22

Tc

00.1

0470

5351

0759

.180

H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l N

ull

Nul

lC

ontig

23

Tc00

.104

7053

5049

29.5

H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l N

ull

Nul

lC

ontig

24

Tc00

.104

7053

5116

11.1

1 H

ypot

hetic

al p

rote

in

Nul

l N

ull

Nul

l N

ull

Con

tig25

Tc

00.1

0470

5350

3975

.20

Hyp

othe

tical

pro

tein

N

ull

Nul

l N

ull

Nul

lC

ontig

26

Tc00

.104

7053

5103

07.6

0 R

etro

trans

poso

n ho

t spo

t pro

tein

N

ull

Nul

l N

ull

Nul

l

(R

HS,

pse

udog

ene)

, put

ativ

e

Supp

lem

enta

ry M

ater

ial S

1. A

nnot

atio

n - O

RES

TES

cont

igs.

Con

tinue

d on

nex

t pag

e

1604


C. Martins et al.

Que

ry

Bes

t bla

stn

hit a

gain

st

Ann

otat

ion

Bes

t bla

stn

hit a

gain

st

EST-

stag

e B

est b

last

x hi

t aga

inst

Pr

oteo

me-

stag

e C

ontig

s R

eads

T.

cru

zi g

enes

and

con

tigs

T.

cru

zi E

STs

T.

cru

zi p

rote

ome

Con

tig27

Tc

00.1

0470

5350

7477

.10

Dis

pers

ed g

ene

fam

ily p

rote

in

Nul

l N

ull

Nul

l

1

(DG

F-1)

, put

ativ

eC

ontig

28

Tc00

.104

7053

5041

05.1

50

Impo

rtin

beta

-1 su

buni

t, pu

tativ

e N

ull

Nul

l N

ull

Nul

lC

ontig

29

Tc00

.104

7053

5116

77.1

0 D

ispe

rsed

gen

e fa

mily

pro

tein

N

ull

Nul

l N

ull

1 (D

GF-

1), p

utat

ive

Con

tig30

Tc

00.1

0470

5350

3547

.20

Dis

pers

ed g

ene

fam

ily p

rote

in 1

TE

NS1

238

T. c

ruzi

epi

mas

tigot

e Ep

imas

tigot

e N

ull

Nul

l

(D

GF-

1, p

seud

ogen

e), p

utat

ive

norm

aliz

ed c

DN

A li

brar

y T.

cru

zi

cDN

A c

lone

123

8 5'

,

mR

NA

sequ

ence

Con

tig31

Tc

00.1

0470

5350

9473

.10

Hyp

othe

tical

pro

tein

(pse

udog

ene)

N

ull

Nul

l N

ull

Nul

lC

ontig

32

Tc00

.104

7053

5104

03.5

0 Re

trotra

nspo

son

hot s

pot p

rote

in

Nul

l N

ull

Nul

l N

ull

(RH

S, p

seud

ogen

e), p

utat

ive

Con

tig33

Tc

00.1

0470

5350

9429

.4

Tran

s-si

alid

ase

(pse

udog

ene)

, N

ull

Nul

l N

ull

Nul

l

pu

tativ

e, 8

096.

t000

37C

ontig

34

Tc00

.104

7053

5101

01.3

40

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

Nul

l N

ull

Con

tig35

Tc

00.1

0470

5339

9389

.10

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

Nul

l N

ull

Con

tig36

Tc

00.1

0470

5350

8647

.220

H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l N

ull

Nul

lC

ontig

37

Tc00

.104

7053

5070

99.4

0 H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l N

ull

Nul

lC

ontig

38

Tc00

.104

7053

5112

83.2

20

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

Nul

l N

ull

Con

tig39

C

ontig

1047

0534

3535

5 N

on-a

nnot

ated

con

tig. L

ikel

y th

e

amas

tc-2

13 T

cAM

T. c

ruzi

cD

NA

A

mas

tigot

e N

ull

Nul

l 10

4705

3435

351

5' m

issi

ng p

art o

f the

cod

ing

cl

one

12D

7 5'

, mR

NA

sequ

ence

regi

on o

f the

5' p

artia

l gen

e

Tc

00.1

0470

5350

6489

.10

1047

0534

3535

5C

ontig

40

Tc00

.104

7053

5082

57.1

70

Dyn

ein

heav

y ch

ain,

put

ativ

e N

ull

Nul

l N

ull

Nul

lC

ontig

41

Tc00

.104

7053

5076

63.5

0 R

NA

hel

icas

e, p

utat

ive

Nul

l N

ull

Nul

l N

ull

Con

tig42

N

ull

Not

iden

tified

N

ull

Nul

l N

ull

Nul

l N

ull

Nul

lC

ontig

43

Tc00

.104

7053

5068

21.2

0 A

TP-d

epen

dent

Clp

pro

teas

e su

buni

t, he

at

Nul

l N

ull

421_

Am

a.m

eta.

epi

Am

astig

ote/

shoc

k pr

otei

n 10

0 (p

seud

ogen

e), p

utat

ive

M

etac

yclic

/

se

rine

pept

idas

e (p

seud

ogen

e), p

utat

ive

Ep

imas

tigot

eC

ontig

44

Tc00

.104

7053

5099

31.2

0 Tr

ans-

sial

idas

e, p

utat

ive

TEN

U48

70 T

. cru

zi e

pim

astig

ote

Ep

imas

tigot

e N

ull

Nul

l

norm

aliz

ed c

DN

A li

brar

y T.

cru

zi

cDN

A c

lone

43g

22 5

',

mR

NA

sequ

ence

Con

tig45

Tc

00.1

0470

5350

5163

.80

Olig

osac

char

yl tr

ansf

eras

e su

buni

t, pu

tativ

e N

ull

Nul

l N

ull

Nul

lC

ontig

46

Tc00

.104

7053

5100

99.1

20

D-is

omer

spec

ific

2-hy

drox

yaci

d

TcA

maP

l06R

un01

_D09

T. c

ruzi

A

mas

tigot

e N

ull

Nul

l

de

hydr

ogen

ase-

prot

ein,

put

ativ

e am

astig

ote

cDN

A li

brar

y T.

cru

zi

cD

NA

5' s

imila

r to

hypo

thet

ical

pr

otei

n, m

RN

A se

quen

ceC

ontig

47

Tc00

.104

7053

5091

71.6

0 H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l N

ull

Nul

l

Supp

lem

enta

ry M

ater

ial S

1. C

ontin

ued.

Con

tinue

d on

nex

t pag

e

1605



Que

ry

Bes

t bla

stn

hit a

gain

st

Ann

otat

ion

Bes

t bla

stn

hit a

gain

st

EST-

stag

e B

est b

last

x hi

t aga

inst

Pr

oteo

me-

stag

e C

ontig

s R

eads

T.

cru

zi g

enes

and

con

tigs

T.

cru

zi E

STs

T.

cru

zi p

rote

ome

Con

tig48

Tc

00.1

0470

5350

6649

.90

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

Nul

l N

ull

Con

tig49

Tc

00.1

0470

5350

6795

.80

Prol

ine

race

mas

e TE

NS2

013

T. c

ruzi

epi

mas

tigot

e

Epim

astig

ote

Nul

l N

ull

no

rmal

ized

cD

NA

libr

ary

T. c

ruzi

cDN

A c

lone

201

3 5'

, mR

NA

sequ

ence

Con

tig50

Tc

00.1

0470

5350

8367

.50

Hyp

othe

tical

pro

tein

, con

serv

ed (p

seud

ogen

e)

TEN

U13

65 T

. cru

zi e

pim

astig

ote

Ep

imas

tigot

e N

ull

Nul

l

norm

aliz

ed c

DN

A li

brar

y T.

cru

zi

cD

NA

clo

ne 2

1e3

3', m

RN

A se

quen

ceC

ontig

51

Tc00

.104

7053

5064

05.1

40

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

Nul

l N

ull

Con

tig52

Tc

00.1

0470

5350

6661

.50

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

Nul

l N

ull

Con

tig53

Tc

00.1

0470

5351

0689

.10

Coa

tom

er a

lpha

subu

nit (

pseu

doge

ne),

puta

tive

Nul

l N

ull

Nul

l N

ull

Con

tig54

Tc

00.1

0470

5350

7099

.80

AB

C tr

ansp

orte

r, pu

tativ

e N

ull

Nul

l N

ull

Nul

lC

ontig

55

Tc00

.104

7053

5037

01.9

D

isper

sed

gene

fam

ily p

rote

in

TcA

maP

l09R

un01

_B10

T. c

ruzi

A

mas

tigot

e 74

3_M

eta

Met

acyc

lic

1

(DG

F-1,

pse

udog

ene)

, put

ativ

e am

astig

ote

cDN

A li

brar

y T.

cru

zi

cD

NA

3' s

imila

r to

cyst

eine

-ric

h

repe

at m

otif,

mR

NA

sequ

ence

Con

tig56

Tc

00.1

0470

5351

0565

.20

Fatty

aci

d de

satu

rase

, put

ativ

e am

astc

-438

TcA

M T

. cru

zi c

DN

A

Am

astig

ote

Nul

l N

ull

cl

one

15A

4 5'

, mR

NA

sequ

ence

Con

tig57

Tc

00.1

0470

5350

4071

.30

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

Nul

l N

ull

Con

tig58

Tc

00.1

0470

5351

1105

.29

Dis

pers

ed g

ene

fam

ily p

rote

in

Nul

l N

ull

Nul

l N

ull

1 (D

GF-

1), p

utat

ive

Con

tig59

N

ull

Not

iden

tified

N

ull

Nul

l N

ull

Nul

l N

ull

Nul

lC

ontig

60

Tc00

.104

7053

5113

93.6

0 Pr

otei

n ki

nase

, put

ativ

e N

ull

Nul

l N

ull

Nul

lC

ontig

61

Tc00

.104

7053

5112

11.1

70

Hea

t sho

ck p

rote

in 7

0 (H

SP70

), pu

tativ

e am

astc

-216

TcA

M T

. cru

zi c

DN

A

Am

astig

ote

257_

Met

a M

etac

yclic

cl

one

12E1

5',

mR

NA

sequ

ence

Con

tig62

Tc

00.1

0470

5350

9157

.170

Tr

ans-

sial

idas

e, p

utat

ive

Nul

l N

ull

Nul

l N

ull

Con

tig63

Tc

00.1

0470

5350

9455

.30

Hyp

othe

tical

pro

tein

, con

serv

ed

TEN

S056

8 T.

cru

zi e

pim

astig

ote

Ep

imas

tigot

e N

ull

Nul

l

norm

aliz

ed c

DN

A li

brar

y T.

cru

zi

cD

NA

clo

ne 5

68 5

', m

RN

A se

quen

ceC

ontig

64

Tc00

.104

7053

5070

83.1

09

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

Nul

l N

ull

Con

tig65

Tc

00.1

0470

5350

9931

.20

Tran

s-si

alid

ase,

put

ativ

e N

ull

Nul

l N

ull

Nul

lC

ontig

66

Tc00

.104

7053

5103

29.1

40

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

Nul

l N

ull

Con

tig67

Tc

00.1

0470

5350

9965

.110

Im

porti

n al

pha,

put

ativ

e Tc

Am

aPl0

9Run

01_G

06 T

. cru

zi

Am

astig

ote

Nul

l N

ull

am

astig

ote

cDN

A li

brar

y T.

cru

zi

cD

NA

3' s

imila

r to

impo

rtin

alph

a-lik

e

prot

ein,

mR

NA

sequ

ence

C

ontig

68

Tc00

.104

7053

5087

99.2

40

Am

inop

eptid

ase,

put

ativ

e N

ull

Nul

l 10

6_Tr

ypo.

met

a.ep

i Tr

ypom

astig

ote/

Met

acyc

lic/

Ep

imas

tigot

e

Supp

lem

enta

ry M

ater

ial S

1. C

ontin

ued.

Con

tinue

d on

nex

t pag

e

1606


C. Martins et al.

Que

ry

Bes

t bla

stn

hit a

gain

st

Ann

otat

ion

Bes

t bla

stn

hit a

gain

st

EST-

stag

e B

est b

last

x hi

t aga

inst

Pr

oteo

me-

stag

e C

ontig

s R

eads

T.

cru

zi g

enes

and

con

tigs

T.

cru

zi E

STs

T.

cru

zi p

rote

ome

Con

tig69

Tc

00.1

0470

5351

1617

.9

NU

P-1

prot

ein

(pse

udog

ene)

, put

ativ

e N

ull

Nul

l N

ull

Nul

lC

ontig

70

Tc00

.104

7053

5112

17.1

20

Cyc

loph

ilin,

put

ativ

e N

ull

Nul

l N

ull

Nul

lC

ontig

71

Tc00

.104

7053

5105

99.7

0 Pr

otam

ine

P1, p

utat

ive

Nul

l N

ull

Nul

l N

ull

Con

tig72

80

94.te

0001

5 D

IRE

TcA

maP

l09R

un01

_A09

T. c

ruzi

A

mas

tigot

e N

ull

Nul

l

amas

tigot

e cD

NA

libr

ary

T. c

ruzi

cD

NA

3' s

imila

r to

hypo

thet

ical

pr

otei

n, m

RN

A se

quen

ceC

ontig

73

1941

7.rr

na00

001

RN

A ri

boso

mal

N

ull

Nul

l N

ull

Nul

lC

ontig

74

Nul

l N

ot id

entifi

ed

Nul

l N

ull

Nul

l N

ull

Nul

l N

ull

Con

tig75

N

ull

195-

bp sa

telli

te D

NA

TE

NU

4403

T. c

ruzi

epi

mas

tigot

e

Epim

astig

ote

Nul

l N

ull

no

rmal

ized

cD

NA

libr

ary

T. c

ruzi

cD

NA

clo

ne 5

h21

3',

m

RN

A se

quen

ceC

ontig

76

Tc00

.104

7053

5077

15.2

0 H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l N

ull

Nul

lC

ontig

77

Nul

l 19

5-bp

sate

llite

DN

A

TEN

U44

03 T

. cru

zi e

pim

astig

ote

Ep

imas

tigot

e N

ull

Nul

l

norm

aliz

ed c

DN

A li

brar

y T.

cru

zi

cDN

A c

lone

5h2

1 3'

,

mR

NA

sequ

ence

C

ontig

78

Nul

l N

ot id

entifi

ed

Nul

l N

ull

Nul

l N

ull

Nul

lC

ontig

79

Tc00

.104

7053

5069

45.2

30

40S

ribos

omal

pro

tein

S14

, put

ativ

e

TEN

U49

84 T

. cru

zi e

pim

astig

ote

Ep

imas

tigot

e N

ull

Nul

l

norm

aliz

ed c

DN

A li

brar

y T.

cru

zi

cDN

A c

lone

43p

12 5

',

mR

NA

sequ

ence

C

ontig

80

Con

tig10

4705

3455

497

Non

-ann

otat

ed c

ontig

- M

axic

ircle

sequ

ence

TE

UF0

146

T. c

ruzi

epi

mas

tigot

e

Epim

astig

ote

Nul

l N

ull

1047

0534

5549

7

non-

norm

aliz

ed c

DN

A li

brar

y T.

cru

zi

cD

NA

clo

ne 1

46 5

' sim

ilar t

o T.

cru

zi

ge

ne fo

r his

tone

H2b

(X60

982)

,

mR

NA

sequ

ence

C

ontig

81

1184

3.rr

na00

002

RN

A ri

boso

mal

N

ull

Nul

l N

ull

Nul

lC

ontig

82

Tc00

.104

7053

5064

71.5

0 Tr

ans-

sial

idas

e (p

seud

ogen

e), p

utat

ive

TE

NU

4870

T. c

ruzi

epi

mas

tigot

e

Epim

astig

ote

Nul

l N

ull

no

rmal

ized

cD

NA

libr

ary

T. c

ruzi

cD

NA

clo

ne 4

3g22

5',

m

RN

A se

quen

ce

Con

tig83

Tc

00.1

0470

5351

0275

.130

D

ispe

rsed

gen

e fa

mily

pro

tein

N

ull

Nul

l N

ull

Nul

l

1

(DG

F-1)

, put

ativ

eC

ontig

84

1941

7.rr

na00

001

RN

A ri

boso

mal

TE

NQ

0845

T. c

ruzi

epi

mas

tigot

e

Epim

astig

ote

Nul

l N

ull

no

rmal

ized

cD

NA

libr

ary

T. c

ruzi

cDN

A, m

RN

A se

quen

ce

Con

tinue

d on

nex

t pag

e

Supp

lem

enta

ry M

ater

ial S

1. C

ontin

ued.

1607



Que

ry

Bes

t bla

stn

hit a

gain

st

Ann

otat

ion

Bes

t bla

stn

hit a

gain

st

EST-

stag

e B

est b

last

x hi

t aga

inst

Pr

oteo

me-

stag

e C

ontig

s R

eads

T.

cru

zi g

enes

and

con

tigs

T.

cru

zi E

STs

T.

cru

zi p

rote

ome

Con

tig85

Tc

00.1

0470

5350

8879

.130

Te

lom

eras

e co

mpo

nent

(pse

udog

ene)

, put

ativ

e N

ull

Nul

l N

ull

Nul

lC

ontig

86

Tc00

.104

7053

5101

87.2

10

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

Nul

l N

ull

Con

tig87

Tc

00.1

0470

5351

1283

.240

H

ypot

hetic

al p

rote

in, c

onse

rved

TE

NU

0619

T. c

ruzi

epi

mas

tigot

e Ep

imas

tigot

e N

ull

Nul

l

norm

aliz

ed c

DN

A li

brar

y T.

cru

zi

cD

NA

clo

ne 3

c1 3

',

mR

NA

sequ

ence

Con

tig88

74

91.te

0001

1 L1

Tc p

oten

tially

func

tiona

l TE

NG

0433

T. c

ruzi

epi

mas

tigot

e

Epim

astig

ote

Nul

l N

ull

no

rmal

ised

cD

NA

libr

ary

T. c

ruzi

cDN

A c

lone

n78

2.r 5

',

mR

NA

sequ

ence

C

ontig

89

Tc00

.104

7053

5074

79.2

9 R

etro

trans

poso

n ho

t spo

t pro

tein

N

ull

Nul

l 48

8_M

eta

Met

acyc

lic

(R

HS,

pse

udog

ene)

, put

ativ

eC

ontig

90

Tc00

.104

7053

5098

65.9

R

etro

trans

poso

n ho

t spo

t (R

HS)

N

ull

Nul

l 23

8_A

ma.

trypo

.met

a A

mas

tigot

e/

pr

otei

n, p

utat

ive

Tr

ypom

astig

ote/

Met

acyc

licC

ontig

91

Tc00

.104

7053

5088

37.3

4 D

ispe

rsed

gen

e fa

mily

pro

tein

Tc

Am

aPl0

9Run

01_B

10 T

. cru

zi

Am

astig

ote

743_

Met

a M

etac

yclic

1 (D

GF-

1), p

utat

ive

amas

tigot

e cD

NA

libr

ary

T. c

ruzi

cDN

A 3

' sim

ilar t

o cy

stei

ne-r

ich

re

peat

mot

if, m

RN

A se

quen

ce

Con

tig92

Tc

00.1

0470

5350

7543

.30

Ret

rotra

nspo

son

hot s

pot p

rote

in

Nul

l N

ull

Nul

l N

ull

(RH

S, p

seud

ogen

e), p

utat

ive

Con

tig93

Tc

00.1

0470

5350

6625

.60

Inos

itol 5

-pho

spha

tase

1, p

utat

ive

Nul

l N

ull

Nul

l N

ull

Con

tig94

Tc

00.1

0470

5351

1675

.3

Hyp

othe

tical

pro

tein

N

ull

Nul

l N

ull

Nul

lC

ontig

95

Tc00

.104

7053

5064

81.3

0 H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l N

ull

Nul

lC

ontig

96

Tc00

.104

7053

5114

15.3

0 R

etro

trans

poso

n ho

t spo

t Pro

tein

N

ull

Nul

l N

ull

Nul

l

(R

HS,

pse

udog

ene)

, put

ativ

e

Supp

lem

enta

ry M

ater

ial S

1. C

ontin

ued.

1608


C. Martins et al.

Que

ry

Bes

t bla

stn

hit a

gain

st

Ann

otat

ion

Bes

t bla

stn

hit a

gain

st

EST-

stag

e B

est b

last

x hi

t aga

inst

Pr

oteo

me-

stag

e C

ontig

s R

eads

T.

cru

zi g

enes

and

con

tigs

T.

cru

zi E

STs

T.

cru

zi p

rote

ome

TCA

006-

IQ22

5C_A

05_.

B_0

1.ab

1 Tc

00.1

0470

5351

1369

.30

Elon

gatio

n fa

ctor

1-a

lpha

TE

NG

0420

T. c

ruzi

epi

mas

tigot

e

Epim

astig

ote

Nul

l N

ull

(E

F-1-

alph

a), p

utat

ive

norm

alis

ed c

DN

A li

brar

y T.

cru

zi

cDN

A c

lone

n76

8.r 5

',

mR

NA

sequ

ence

TC

A00

6-IQ

225C

_A06

_.B

_02.

ab1

Tc00

.104

7053

5081

43.9

0 Tr

ans-

sial

idas

e (p

seud

ogen

e), p

utat

ive

Nul

l N

ull

Nul

l N

ull

TC

A00

6-IQ

225C

_A07

_.B

_01.

ab1

Tc00

.104

7053

5065

31.4

0 H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l N

ull

Nul

l

TCA

006-

IQ22

5C_A

10_.

B_0

2.ab

1 Tc

00.1

0470

5351

1249

.110

K

ines

in K

39 (p

seud

ogen

e), p

utat

ive

Nul

l N

ull

Nul

l N

ull

TC

A00

6-IQ

225C

_A12

_.B

_02.

ab1

Tc00

.104

7053

5101

23.1

0 H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l N

ull

Nul

l

TCA

006-

IQ22

5C_B

03_.

B_0

3.ab

1 Tc

00.1

0470

5350

4277

.30

Hyp

othe

tical

pro

tein

N

ull

Nul

l N

ull

Nul

l

TCA

006-

IQ22

5C_B

06_.

B_0

4.ab

1 Tc

00.1

0470

5351

1173

.64

Muc

in-a

ssoc

iate

d su

rfac

e pr

otei

n

TEN

S242

2 T.

cru

zi e

pim

astig

ote

Epim

astig

ote

Nul

l N

ull

(M

ASP

), pu

tativ

e no

rmal

ized

cDN

A lib

rary

T. c

ruzi

cD

NA

clon

e 24

22 5

',

mR

NA

sequ

ence

TCA

006-

IQ22

5C_B

08_.

B_0

4.ab

1 Tc

00.1

0470

5350

7583

.60

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

Nul

l N

ull

TC

A00

6-IQ

225C

_B09

_.B

_03.

ab1

Tc00

.104

7053

5079

41.1

00

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

Nul

l N

ull

TC

A00

6-IQ

225C

_B10

_.B

_04.

ab1

Tc00

.104

7053

5119

03.1

40

Tubu

lin fo

ldin

g co

fact

or

Nul

l N

ull

Nul

l N

ull

D

(pse

udog

ene)

, put

ativ

eTC

A00

6-IQ

225C

_C01

_.B

_05.

ab1

Tc00

.104

7053

5101

01.3

40

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

Nul

l N

ull

TC

A00

6-IQ

225C

_C03

_.B

_05.

ab1

Tc00

.104

7053

5043

93.1

0 H

ypot

hetic

al p

rote

in

TEN

G05

14 T

. cru

zi e

pim

astig

ote

Ep

imas

tigot

e N

ull

Nul

l

no

rmal

ised

cD

NA

libr

ary

T. c

ruzi

cD

NA

clo

ne n

894.

r 5',

m

RNA

sequ

ence

TC

A00

6-IQ

225C

_C04

_.B

_06.

ab1

Tc00

.104

7053

5067

97.2

0 H

ypot

hetic

al p

rote

in

Nul

l N

ull

Nul

l N

ull

TC

A00

6-IQ

225C

_C05

_.B

_05.

ab1

Tc00

.104

7053

4040

01.2

0 H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l N

ull

Nul

l

TCA

006-

IQ22

5C_C

06_.

B_0

6.ab

1 Tc

00.1

0470

5350

6203

.40

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

Nul

l N

ull

TC

A00

6-IQ

225C

_C12

_.B

_06.

ab1

Tc00

.104

7053

5100

13.2

6 Su

rfac

e pr

otea

se G

P63

N

ull

Nul

l N

ull

Nul

l

(pse

udog

ene)

, put

ativ

eTC

A00

6-IQ

225C

_D01

_.B

_07.

ab1

Tc00

.104

7053

5108

77.1

90

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

Nul

l N

ull

TC

A00

6-IQ

225C

_D03

_.B

_07.

ab1

Tc00

.104

7053

5111

93.9

D

ispe

rsed

gen

e fa

mily

pro

tein

N

ull

Nul

l N

ull

Nul

l

1 (D

GF-

1, p

seud

ogen

e), p

utat

ive

TCA

006-

IQ22

5C_D

04_.

B_0

8.ab

1 Tc

00.1

0470

5350

8811

.55

Hyp

othe

tical

pro

tein

am

astc

-122

5 Tc

AM

T. c

ruzi

A

mas

tigot

e N

ull

Nul

l

cD

NA

clo

ne 9

G8

5',

m

RN

A se

quen

ce

TCA

006-

IQ22

5C_D

07_.

B_0

7.ab

1 Tc

00.1

0470

5350

9011

.90

Lipa

se, p

utat

ive

Nul

l N

ull

Nul

l N

ull

TC

A00

6-IQ

225C

_D08

_.B

_08.

ab1

Tc00

.104

7053

5076

41.2

50

Hyp

othe

tical

pro

tein

N

ull

Nul

l N

ull

Nul

l

TCA

006-

IQ22

5C_D

09_.

B_0

7.ab

1 Tc

00.1

0470

5346

6531

.9

Dis

pers

ed g

ene

fam

ily p

rote

in

Nul

l N

ull

Nul

l N

ull

1

(DG

F-1)

, put

ativ

e

Supp

lem

enta

ry M

ater

ial S

1. A

nnot

atio

n - O

RES

TES

sing

leto

ns.

Con

tinue

d on

nex

t pag

e

1609



Que

ry

Bes

t bla

stn

hit a

gain

st

Ann

otat

ion

Bes

t bla

stn

hit a

gain

st

EST-

stag

e B

est b

last

x hi

t aga

inst

Pr

oteo

me-

stag

e C

ontig

s R

eads

T.

cru

zi g

enes

and

con

tigs

T.

cru

zi E

STs

T.

cru

zi p

rote

ome

TCA

006-

IQ22

5C_D

10_.

B_0

8.ab

1 Tc

00.1

0470

5350

6401

.240

H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l N

ull

Nul

l

TCA

006-

IQ22

5C_E

01_.

B_0

9.ab

1 Tc

00.1

0470

5351

0565

.179

H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l N

ull

Nul

l

TCA

006-

IQ22

5C_E

04_.

B_1

0.ab

1 Tc

00.1

0470

5350

4277

.30

Hyp

othe

tical

pro

tein

SG

-4-6

T. c

ruzi

diff

eren

tial

Not

spec

ified

N

ull

Nul

l

di

spla

y cD

NA

libr

ary

T. c

ruzi

cDN

A, m

RN

A se

quen

ce

TCA

006-

IQ22

5C_E

06_.

B_1

0.ab

1 Tc

00.1

0470

5351

0533

.210

H

ypot

hetic

al p

rote

in,

Nul

l N

ull

Nul

l N

ull

co

nser

ved

(pse

udog

ene)

TCA

006-

IQ22

5C_E

08_.

B_1

0.ab

1 Tc

00.1

0470

5350

8781

.70

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

Nul

l N

ull

TC

A00

6-IQ

225C

_E11

_.B

_09.

ab1

NU

LL

Not

iden

tified

N

ull

Nul

l N

ull

Nul

l

Nul

l N

ull

TCA

006-

IQ22

5C_F

03_.

B_1

1.ab

1 Tc

00.1

0470

5351

0791

.60

Muc

in-a

ssoc

iate

d su

rfac

e pr

otei

n

TcA

maP

l09R

un01

_F04

A

mas

tigot

e N

ull

Nul

l

(M

ASP

, pse

udog

ene)

, put

ativ

e T.

cru

zi a

mas

tigot

e cD

NA

libra

ry T

. cru

zi c

DN

A

3'

sim

ilar t

o ga

g-re

late

d

prot

ein,

mR

NA

sequ

ence

TCA

006-

IQ22

5C_F

04_.

B_1

2.ab

1 Tc

00.1

0470

5351

1819

.59

Dyn

ein

heav

y ch

ain,

cyt

osol

ic, p

utat

ive

Nul

l N

ull

Nul

l N

ull

TC

A00

6-IQ

225C

_F08

_.B

_12.

ab1

Tc00

.104

7053

5098

71.8

0 D

ispe

rsed

gen

e fa

mily

pro

tein

TE

NS1

221

T. c

ruzi

epi

mas

tigot

e

Epim

astig

ote

Nul

l N

ull

1

(DG

F-1)

, put

ativ

e no

rmal

ized

cD

NA

libr

ary

T.

cru

zi c

DN

A c

lone

122

1 5'

,

mR

NA

sequ

ence

TCA

006-

IQ22

5C_G

02_.

B_1

4.ab

1 Tc

00.1

0470

5350

4929

.5

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

Nul

l N

ull

TC

A00

6-IQ

225C

_G05

_.B

_13.

ab1

Tc00

.104

7053

5069

49.2

0 H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l 43

5_M

eta.

epi

Met

acyc

lic,

epim

astig

ote

TC

A00

6-IQ

225C

_G06

_.B

_14.

ab1

Tc00

.104

7053

5111

33.3

0 H

ypot

hetic

al p

rote

in, c

onse

rved

TE

NU

0543

T. c

ruzi

epi

mas

tigot

e

Epim

astig

ote

Nul

l N

ull

norm

aliz

ed c

DN

A li

brar

y T.

cru

zi

cDN

A c

lone

8h4

3',

m

RN

A se

quen

ce

TCA

006-

IQ22

5C_G

07_.

B_1

3.ab

1 Tc

00.1

0470

5350

8165

.430

Tr

ans-

sial

idas

e, p

utat

ive

Nul

l N

ull

Nul

l N

ull

TC

A00

6-IQ

225C

_G11

_.B

_13.

ab1

Tc00

.104

7053

5067

99.1

50

Surf

ace

prot

ease

GP6

3

Nul

l N

ull

Nul

l N

ull

(p

seud

ogen

e), p

utat

ive

TCA

006-

IQ22

5C_H

02_.

B_1

6.ab

1 Tc

00.1

0470

5350

9775

.30

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

Nul

l N

ull

TC

A00

6-IQ

225C

_H04

_.B

_16.

ab1

Tc00

.104

7053

5064

01.7

0 Va

cuol

ar p

rote

in so

rting

N

ull

Nul

l N

ull

Nul

l

prot

ein

18, p

utat

ive

TCA

006-

IQ22

5C_H

05_.

B_1

5.ab

1 Tc

00.1

0470

5350

8277

.380

H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l N

ull

Nul

l

TCA

006-

IQ22

5C_H

08_.

B_1

6.ab

1 Tc

00.1

0470

5350

3881

.20

GD

P-m

anno

se 4

,6 d

ehyd

rata

se, p

utat

ive

Nul

l N

ull

Nul

l N

ull

TC

A00

6-IQ

225C

_H10

_.B

_16.

ab1

Tc00

.104

7053

5074

27.3

0 R

etro

trans

poso

n ho

t spo

t pro

tein

N

ull

Nul

l 76

1_M

eta.

epi

Met

acyc

lic,

(RH

S, p

seud

ogen

e), p

utat

ive

ep

imas

tigot

e TC

A00

6-IQ

225C

_H11

_.B

_15.

ab1

Nul

l N

ot id

entifi

ed

Nul

l N

ull

Nul

l N

ull

N

ull

Nul

l

Supp

lem

enta

ry M

ater

ial S

1. C

ontin

ued.

Con

tinue

d on

nex

t pag

e

1610


C. Martins et al.

Que

ry

Bes

t bla

stn

hit a

gain

st

Ann

otat

ion

Bes

t bla

stn

hit a

gain

st

EST-

stag

e B

est b

last

x hi

t aga

inst

Pr

oteo

me-

stag

e C

ontig

s R

eads

T.

cru

zi g

enes

and

con

tigs

T.

cru

zi E

STs

T.

cru

zi p

rote

ome

TCA

006-

IQ22

5C_H

12_.

B_1

6.ab

1 N

ull

Not

iden

tified

N

ull

Nul

l N

ull

Nul

l N

ull

Nul

lTC

A00

6-IQ

225E

_A03

_.B

_01.

ab1

Tc00

.104

7053

5079

53.1

30

Hyp

othe

tical

pro

tein

TE

NU

4024

T. c

ruzi

epi

mas

tigot

e

Epim

astig

ote

Nul

l N

ull

norm

aliz

ed c

DN

A li

brar

y T.

cru

zi

cDN

A c

lone

1l2

3',

m

RN

A se

quen

ce

TCA

006-

IQ22

5E_A

04_.

B_0

2.ab

1 Tc

00.1

0470

5350

3697

.60

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

Nul

l N

ull

TC

A00

6-IQ

225E

_A06

_.B

_02.

ab1

Tc00

.104

7053

5082

13.3

0 H

ypot

hetic

al p

rote

in

Nul

l N

ull

Nul

l N

ull

TC

A00

6-IQ

225E

_A08

_.B

_02.

ab1

Tc00

.104

7053

5101

71.1

0 Tr

ans-

sial

idas

e, p

utat

ive

Nul

l N

ull

Nul

l N

ull

TC

A00

6-IQ

225E

_A09

_.B

_01.

ab1

Tc00

.104

7053

5089

49.1

0 H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l N

ull

Nul

l

TCA

006-

IQ22

5E_A

10_.

B_0

2.ab

1 Tc

00.1

0470

5350

9433

.30

Hyp

othe

tical

pro

tein

N

ull

Nul

l N

ull

Nul

l

TCA

006-

IQ22

5E_B

02_.

B_0

4.ab

1 Tc

00.1

0470

5351

0101

.340

H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l N

ull

Nul

lTC

A00

6-IQ

225E

_B03

_.B

_03.

ab1

Tc00

.104

7053

5069

61.1

30

Ret

rotra

nspo

son

hot s

pot p

rote

in

Nul

l N

ull

761_

Met

a.ep

i M

etac

yclic

,

(R

HS,

pse

udog

ene)

, put

ativ

e

epim

astig

ote

TCA

006-

IQ22

5E_C

01_.

B_0

5.ab

1 Tc

00.1

0470

5351

0985

.10

Tran

s-si

alid

ase,

put

ativ

e N

ull

Nul

l N

ull

Nul

l

TCA

006-

IQ22

5E_C

03_.

B_0

5.ab

1 Tc

00.1

0470

5350

8277

.350

C

atio

n tra

nspo

rter,

puta

tive

Nul

l N

ull

Nul

l N

ull

TC

A00

6-IQ

225E

_C07

_.B

_05.

ab1

Nul

l N

ot id

entifi

ed

Nul

l N

ull

Nul

l N

ull

Nul

l N

ull

TCA

006-

IQ22

5E_C

09_.

B_0

5.ab

1 Tc

00.1

0470

5350

6321

.270

H

ypot

hetic

al p

rote

in, c

onse

rved

TE

NU

2275

T. c

ruzi

epi

mas

tigot

e

Epim

astig

ote

Nul

l N

ull

no

rmal

ized

cD

NA

libr

ary

T. c

ruzi

cD

NA

clo

ne 1

0k16

3’,

m

RN

A se

quen

ceTC

A00

6-IQ

225E

_C12

_.B

_06.

ab1

Nul

l N

ot id

entifi

ed

Nul

l N

ull

Nul

l N

ull

Nul

l N

ull

TCA

006-

IQ22

5E_D

01_.

B_0

7.ab

1 N

ull

Not

iden

tified

N

ull

Nul

l N

ull

Nul

l N

ull

Nul

lTC

A00

6-IQ

225E

_D08

_.B

_08.

ab1

Tc00

.104

7053

5072

11.2

0 Pr

otei

n ki

nase

, put

ativ

e N

ull

Nul

l N

ull

Nul

l

TCA

006-

IQ22

5E_D

09_.

B_0

7.ab

1 Tc

00.1

0470

5351

0325

.69

Am

inop

eptid

ase,

put

ativ

e N

ull

Nul

l N

ull

Nul

l

TCA

006-

IQ22

5E_D

10_.

B_0

8.ab

1 Tc

00.1

0470

5350

6799

.10

Fatty

aci

d tra

nspo

rter

Nul

l N

ull

Nul

l N

ull

pr

otei

n-lik

e, p

utat

ive

TCA

006-

IQ22

5E_D

11_.

B_0

7.ab

1 C

ontig

1047

0535

0404

5 M

atch

es th

e 3’

end

of t

he

Nul

l N

ull

Nul

l N

ull

1047

0535

0404

5

co

ding

regi

on o

f the

gen

e

Tc

00.1

0470

5350

4045

.50

and

dow

nstre

am fl

anki

ng re

gion

TCA

006-

IQ22

5E_D

12_.

B_0

8.ab

1 Tc

00.1

0470

5350

8325

.290

Tr

ans-

sial

idas

e (p

seud

ogen

e),

Nul

l N

ull

Nul

l N

ull

pu

tativ

eTC

A00

6-IQ

225E

_E04

_.B

_10.

ab1

Tc00

.104

7053

5101

67.2

9 Ex

osom

e co

mpl

ex

Nul

l N

ull

Nul

l N

ull

ex

onuc

leas

e, p

utat

ive

TCA

006-

IQ22

5E_E

08_.

B_1

0.ab

1 Tc

00.1

0470

5350

8173

.264

H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l N

ull

Nul

l

TCA

006-

IQ22

5E_E

11_.

B_0

9.ab

1 Tc

00.1

0470

5350

3803

.10

rRN

A b

ioge

nesi

s pro

tein

, put

ativ

e N

ull

Nul

l N

ull

Nul

l

TCA

006-

IQ22

5E_E

12_.

B_1

0.ab

1 N

ull

Not

iden

tified

N

ull

Nul

l N

ull

Nul

l N

ull

Nul

l

Supp

lem

enta

ry M

ater

ial S

1. C

ontin

ued.

Con

tinue

d on

nex

t pag

e

1611



Con

tinue

d on

nex

t pag

e

Que

ry

Bes

t bla

stn

hit a

gain

st

Ann

otat

ion

Bes

t bla

stn

hit a

gain

st

EST-

stag

e B

est b

last

x hi

t aga

inst

Pr

oteo

me-

stag

e C

ontig

s R

eads

T.

cru

zi g

enes

and

con

tigs

T.

cru

zi E

STs

T.

cru

zi p

rote

ome

TCA

006-

IQ22

5E_F

03_.

B_1

1.ab

1 Tc

00.1

0470

5350

6243

.94

Ret

rotra

nspo

son

hot s

pot p

rote

in

Nul

l N

ull

Nul

l N

ull

(R

HS,

pse

udog

ene)

, put

ativ

eTC

A00

6-IQ

225E

_F07

_.B

_11.

ab1

Tc00

.104

7053

5087

19.9

H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l N

ull

Nul

l

TCA

006-

IQ22

5E_F

10_.

B_1

2.ab

1 Tc

00.1

0470

5350

7747

.10

Surf

ace

prot

ease

GP6

3, p

utat

ive

Nul

l N

ull

571_

Met

a M

etac

yclic

TCA

006-

IQ22

5E_F

11_.

B_1

1.ab

1 Tc

00.1

0470

5350

7809

.60

Hyp

othe

tical

pro

tein

, con

serv

ed

TEN

S228

9 T.

cru

zi e

pim

astig

ote

Ep

imas

tigot

e N

ull

Nul

l

no

rmal

ized

cD

NA

libr

ary

T. c

ruzi

cD

NA

clo

ne 2

289

5',

m

RN

A se

quen

ce

TCA

006-

IQ22

5E_F

12_.

B_1

2.ab

1 N

ull

Not

iden

tified

N

ull

Nul

l N

ull

Nul

l N

ull

Nul

lTC

A00

6-IQ

225E

_G03

_.B

_13.

ab1

Tc00

.104

7053

5108

57.1

0 H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l N

ull

Nul

l

TCA

006-

IQ22

5E_G

04_.

B_1

4.ab

1 Tc

00.1

0470

5350

9171

.70

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

Nul

l N

ull

TCA

006-

IQ22

5E_G

05_.

B_1

3.ab

1 Tc

00.1

0470

5351

0053

.79

FG-G

AP

repe

at p

rote

in, p

utat

ive

Nul

l N

ull

Nul

l N

ull

TC

A00

6-IQ

225E

_H01

_.B

_15.

ab1

Tc00

.104

7053

4539

17.9

H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l 33

_Try

po.m

eta

Tryp

omas

tigot

e,

met

acyc

licTC

A00

6-IQ

225E

_H02

_.B

_16.

ab1

Tc00

.104

7053

5067

95.9

0 H

ypot

hetic

al p

rote

in, c

onse

rved

TE

NU

0078

T. c

ruzi

epi

mas

tigot

e

Epim

astig

ote

Nul

l N

ull

norm

aliz

ed c

DN

A li

brar

y T.

cru

zi

cDN

A c

lone

5e1

1 3’

,

mR

NA

sequ

ence

TC

A00

6-IQ

225E

_H05

_.B

_15.

ab1

Tc00

.104

7053

5068

11.1

60

R27

-2 p

rote

in, p

utat

ive

Nul

l N

ull

Nul

l N

ull

TC

A00

6-IQ

225E

_H06

_.B

_16.

ab1

Tc00

.104

7053

5038

93.1

70

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

Nul

l N

ull

TC

A00

6-IQ

225E

_H07

_.B

_15.

ab1

Tc00

.104

7053

5094

51.7

0 H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l N

ull

Nul

l

TCA

006-

IQ22

5E_H

09_.

B_1

5.ab

1 Tc

00.1

0470

5350

6925

.70

Epsi

n, p

utat

ive

Nul

l N

ull

Nul

l N

ull

TC

A00

6-IQ

225E

_H11

_.B

_15.

ab1

Nul

l N

ot id

entifi

ed

Nul

l N

ull

Nul

l N

ull

Nul

l N

ull

TCA

006-

IQ22

5F_A

02_.

b_02

.ab1

N

ull

Not

iden

tified

N

ull

Nul

l N

ull

Nul

l N

ull

Nul

lTC

A00

6-IQ

225F

_A04

_.b_

02.a

b1

Tc00

.104

7053

5101

01.3

40

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

Nul

l N

ull

TC

A00

6-IQ

225F

_A10

_.b_

02.a

b1

Tc00

.104

7053

5084

45.1

0 ra

b11B

GTP

ase,

put

ativ

e N

ull

Nul

l N

ull

Nul

l

TCA

006-

IQ22

5F_B

01_.

b_03

.ab1

Tc

00.1

0470

5350

9979

.249

Sy

ntax

in b

indi

ng p

rote

in

Nul

l N

ull

Nul

l N

ull

1

(pse

udog

ene)

, put

ativ

eTC

A00

6-IQ

225F

_C01

_.b_

05.a

b1

Tc00

.104

7053

5041

05.1

30

Cal

cium

cha

nnel

pro

tein

, put

ativ

e N

ull

Nul

l N

ull

Nul

l

TCA

006-

IQ22

5F_C

03_.

b_05

.ab1

N

ull

Not

iden

tified

N

ull

Nul

l N

ull

Nul

l N

ull

Nul

lTC

A00

6-IQ

225F

_C07

_.b_

05.a

b1

Tc00

.104

7053

5101

01.3

40

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

Nul

l N

ull

TC

A00

6-IQ

225F

_C11

_.b_

05.a

b1

Tc00

.104

7053

5092

33.7

0 A

AA

ATP

ase,

put

ativ

e TE

NU

3420

T. c

ruzi

epi

mas

tigot

e

Epim

astig

ote

Nul

l N

ull

norm

aliz

ed c

DN

A li

brar

y T.

cru

zi

cDN

A c

lone

29c

14 5

’,

mR

NA

sequ

ence

TC

A00

6-IQ

225F

_D03

_.b_

07.a

b1

Tc00

.104

7053

5096

41.6

0 H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l N

ull

Nul

l

Supp

lem

enta

ry M

ater

ial S

1. C

ontin

ued.

1612


C. Martins et al.

Que

ry

Bes

t bla

stn

hit a

gain

st

Ann

otat

ion

Bes

t bla

stn

hit a

gain

st

EST-

stag

e B

est b

last

x hi

t aga

inst

Pr

oteo

me-

stag

e C

ontig

s R

eads

T.

cru

zi g

enes

and

con

tigs

T.

cru

zi E

STs

T.

cru

zi p

rote

ome

TCA

006-

IQ22

5F_D

04_.

b_08

.ab1

Tc

00.1

0470

5350

3715

.40

Prot

ein

kina

se, p

utat

ive

Nul

l N

ull

62_a

ma.

epi

Am

astig

ote,

ep

imas

tigot

e

TCA

006-

IQ22

5F_E

01_.

b_09

.ab1

N

ull

Not

iden

tified

N

ull

Nul

l N

ull

Nul

l N

ull

Nul

lTC

A00

6-IQ

225F

_E07

_.b_

09.a

b1

Tc00

.104

7053

4136

05.1

0 K

ines

in, p

utat

ive

Nul

l N

ull

Nul

l N

ull

TC

A00

6-IQ

225F

_E08

_.b_

10.a

b1

Tc00

.104

7053

5062

65.1

00

ATP-

depe

nden

t RN

A h

elic

ase,

put

ativ

e N

ull

Nul

l N

ull

Nul

l

TCA

006-

IQ22

5F_F

05_.

b_11

.ab1

Tc

00.1

0470

5351

1745

.10

Hea

t sho

ck 7

0 kD

a pr

otei

n,

TEN

F015

2 T.

cru

zi

Epim

astig

ote

Nul

l N

ull

mito

chon

dria

l pre

curs

or, p

utat

ive

epim

astig

ote

norm

aliz

ed

cD

NA

libr

ary

T. c

ruzi

cDN

A c

lone

152

5' s

imila

r

to m

itoch

ondr

ial H

sp70

,

mR

NA

sequ

ence

TC

A00

6-IQ

225F

_F12

_.b_

12.a

b1

Tc00

.104

7053

5081

73.6

0 C

is-p

reny

ltran

sfer

ase,

put

ativ

e N

ull

Nul

l N

ull

Nul

l

TCA

006-

IQ22

5F_G

01_.

b_13

.ab1

Tc

00.1

0470

5350

6797

.10

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

Nul

l N

ull

TC

A00

6-IQ

225F

_G08

_.b_

14.a

b1

Tc00

.104

7053

5047

97.1

44

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

Nul

l N

ull

TC

A00

6-IQ

225F

_H01

_.b_

15.a

b1

Nul

l N

ot id

entifi

ed

Nul

l N

ull

Nul

l N

ull

Nul

l N

ull

TCA

006-

IQ22

5F_H

02_.

b_16

.ab1

Tc

00.1

0470

5351

0281

.20

Surf

ace

prot

ease

GP6

3, p

utat

ive

Nul

l N

ull

Nul

l N

ull

TC

A00

6-IQ

225F

_H04

_.b_

16.a

b1

Con

tig10

4705

3503

717

Mat

ches

the

inte

r-cod

ing

N

ull

Nul

l N

ull

Nul

l 10

4705

3503

717

regi

on o

f the

gen

es

Tc00

.104

7053

5037

17.9

0

an

d Tc

00.1

0470

5350

3717

.120

TCA

006-

IQ22

5F_H

07_.

b_15

.ab1

Tc

00.1

0470

5350

4427

.30

Hyp

othe

tical

pro

tein

, con

serv

ed

TEN

U11

96 T

. cru

zi

Epim

astig

ote

Nul

l N

ull

epim

astig

ote

norm

aliz

ed

cD

NA

libr

ary

T. c

ruzi

cDN

A c

lone

20i

24 3

’,

mR

NA

sequ

ence

TC

A00

6-IQ

225F

_H08

_.b_

16.a

b1

Tc00

.104

7053

5096

95.1

50

Kin

esin

, put

ativ

e N

ull

Nul

l N

ull

Nul

l

TCA

006-

IQ22

5G_A

01_.

b_01

.ab1

Tc

00.1

0470

5351

0423

.40

Hyp

othe

tical

pro

tein

, con

serv

ed

amas

tc-1

111

TcA

M T

. cru

zi

Am

astig

ote

Nul

l N

ull

cDN

A c

lone

8E1

1 5’

,

mR

NA

sequ

ence

TC

A00

6-IQ

225G

_A05

_.b_

01.a

b1

Tc00

.104

7053

5062

13.6

0 40

S rib

osom

al p

rote

in S

2, p

utat

ive

amas

tc-1

15 T

cAM

T. c

ruzi

A

mas

tigot

e 37

_am

a.ep

i A

mas

tigot

e,

cDN

A c

lone

11D

2 5’

,

ep

imas

tigot

e

mR

NA

sequ

ence

TC

A00

6-IQ

225G

_A07

_.b_

01.a

b1

Tc00

.104

7053

5064

39.1

8 H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l N

ull

Nul

l

TCA

006-

IQ22

5G_A

08_.

b_02

.ab1

Tc

00.1

0470

5350

6401

.290

H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l N

ull

Nul

l

TCA

006-

IQ22

5G_A

12_.

b_02

.ab1

N

ull

Not

iden

tified

N

ull

Nul

l N

ull

Nul

l N

ull

Nul

lTC

A00

6-IQ

225G

_B02

_.b_

04.a

b1

Tc00

.104

7053

5118

27.1

10

Tran

s-si

alid

ase,

put

ativ

e N

ull

Nul

l N

ull

Nul

l

Supp

lem

enta

ry M

ater

ial S

1. C

ontin

ued.

Con

tinue

d on

nex

t pag

e

1613



Que

ry

Bes

t bla

stn

hit a

gain

st

Ann

otat

ion

Bes

t bla

stn

hit a

gain

st

EST-

stag

e B

est b

last

x hi

t aga

inst

Pr

oteo

me-

stag

e C

ontig

s R

eads

T.

cru

zi g

enes

and

con

tigs

T.

cru

zi E

STs

T.

cru

zi p

rote

ome

TCA

006-

IQ22

5G_B

04_.

b_04

.ab1

Tc

00.1

0470

5350

9887

.19

Dis

pers

ed g

ene

fam

ily p

rote

in

Nul

l N

ull

Nul

l N

ull

1

(DG

F-1)

, put

ativ

eTC

A00

6-IQ

225G

_B09

_.b_

03.a

b1

Tc00

.104

7053

5117

79.6

0 Tr

ans-

sial

idas

e, p

utat

ive

Nul

l N

ull

Nul

l N

ull

TC

A00

6-IQ

225G

_B11

_.b_

03.a

b1

Tc00

.104

7053

5075

05.1

0 Tr

ans-

sial

idas

e, p

utat

ive

TEN

S077

9 T.

cru

zi

Epim

astig

ote

Nul

l N

ull

epim

astig

ote

norm

aliz

ed

cD

NA

libr

ary

T. c

ruzi

cDN

A c

lone

779

5',

m

RN

A se

quen

ce

TCA

006-

IQ22

5G_B

12_.

b_04

.ab1

N

ull

Not

iden

tified

N

ull

Nul

l N

ull

Nul

l N

ull

Nul

lTC

A00

6-IQ

225G

_C01

_.b_

05.a

b1

Tc00

.104

7053

5070

19.1

0 Pr

otei

n ki

nase

, put

ativ

e N

ull

Nul

l N

ull

Nul

lTC

A00

6-IQ

225G

_C06

_.b_

06.a

b1

Tc00

.104

7053

5107

73.9

H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l N

ull

Nul

l

TCA

006-

IQ22

5G_C

07_.

b_05

.ab1

Tc

00.1

0470

5341

4243

.20

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

Nul

l N

ull

TC

A00

6-IQ

225G

_C10

_.b_

06.a

b1

Tc00

.104

7053

5118

25.1

10

Hyp

othe

tical

pro

tein

TE

NF0

697

T. c

ruzi

Ep

imas

tigot

e N

ull

Nul

l

ep

imas

tigot

e no

rmal

ized

cDN

A li

brar

y T.

cru

zi

cD

NA

clo

ne 6

97 5

',

mR

NA

sequ

ence

TC

A00

6-IQ

225G

_C11

_.b_

05.a

b1

Tc00

.104

7053

5091

69.1

0 H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l N

ull

Nul

l

TCA

006-

IQ22

5G_C

12_.

b_06

.ab1

N

ull

Not

iden

tified

N

ull

Nul

l 66

_am

a.ep

i A

mas

tigot

e,

Nul

l N

ull

epim

astig

ote

TCA

006-

IQ22

5G_D

06_.

b_08

.ab1

Tc

00.1

0470

5350

6305

.5

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

Nul

l N

ull

TC

A00

6-IQ

225G

_D10

_.b_

08.a

b1

Tc00

.104

7053

5099

21.6

0 D

ispe

rsed

gen

e fa

mily

pro

tein

TE

NU

4582

T. c

ruzi

Ep

imas

tigot

e 21

1_Ep

i Ep

imas

tigot

e

1 (D

GF-

1), p

utat

ive

epim

astig

ote

norm

aliz

ed

cD

NA

libr

ary

T. c

ruzi

cDN

A c

lone

9o9

3',

m

RN

A se

quen

ce

TCA

006-

IQ22

5G_E

02_.

b_10

.ab1

Tc

00.1

0470

5350

9589

.50

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

Nul

l N

ull

TC

A00

6-IQ

225G

_E05

_.b_

09.a

b1

Tc00

.104

7053

5079

63.3

0 H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l N

ull

Nul

l

TCA

006-

IQ22

5G_E

11_.

b_09

.ab1

C

ontig

1047

0534

4825

1 N

on-a

nnot

ated

con

tig -

likel

y th

e

TcA

maP

l03R

un01

_F04

A

mas

tigot

e N

ull

Nul

l 10

4705

3448

251

3’ e

nd m

issi

ng p

art o

f the

cod

ing

T.

cru

zi a

mas

tigot

e cD

NA

regi

on o

f the

par

tial g

ene

lib

rary

T. c

ruzi

cDN

A 5

',

Tc

00.1

0470

5351

0771

.9

mR

NA

sequ

ence

TCA

006-

IQ22

5G_F

08_.

b_12

.ab1

Tc

00.1

0470

5350

8731

.40

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

Nul

l N

ull

TC

A00

6-IQ

225G

_F09

_.b_

11.a

b1

Tc00

.104

7053

5110

01.8

0 H

ypot

hetic

al p

rote

in, c

onse

rved

am

astc

-156

TcA

M T

. cru

zi

Am

astig

ote

Nul

l N

ull

cDN

A c

lone

11H

1 5'

,

mR

NA

sequ

ence

Supp

lem

enta

ry M

ater

ial S

1. C

ontin

ued.

Con

tinue

d on

nex

t pag

e

1614


C. Martins et al.

Que

ry

Bes

t bla

stn

hit a

gain

st

Ann

otat

ion

Bes

t bla

stn

hit a

gain

st

EST-

stag

e B

est b

last

x hi

t aga

inst

Pr

oteo

me-

stag

e C

ontig

s R

eads

T.

cru

zi g

enes

and

con

tigs

T.

cru

zi E

STs

T.

cru

zi p

rote

ome

TCA

006-

IQ22

5G_F

10_.

b_12

.ab1

25

661.

rrna

0000

1 R

NA

ribo

som

al

TEN

U05

43 T

. cru

zi

Epim

astig

ote

Nul

l N

ull

epim

astig

ote

norm

aliz

ed

cD

NA

libr

ary

T. c

ruzi

cDN

A c

lone

8h4

3',

m

RN

A se

quen

ceTC

A00

6-IQ

225G

_F12

_.b_

12.a

b1

Tc00

.104

7053

5038

33.5

0 H

ypot

hetic

al p

rote

in, c

onse

rved

TE

NG

0126

T. c

ruzi

Ep

imas

tigot

e N

ull

Nul

l

ep

imas

tigot

e no

rmal

ised

cDN

A li

brar

y T.

cru

zi

cDN

A c

lone

n12

6.r 5

’,

mR

NA

sequ

ence

TC

A00

6-IQ

225G

_G02

_.b_

14.a

b1

9441

.rrna

0000

1 R

NA

ribo

som

al

Nul

l N

ull

Nul

l N

ull

TC

A00

6-IQ

225G

_G03

_.b_

13.a

b1

Tc00

.104

7053

5097

33.1

00

Tran

slat

ion

elon

gatio

n fa

ctor

Tc

Am

aPl0

7Run

01_H

04

Am

astig

ote

Nul

l N

ull

1-

beta

, put

ativ

e T.

cru

zi a

mas

tigot

e cD

NA

libra

ry T

. cru

zi c

DN

A 3

’

sim

ilar t

o el

onga

tion

fact

or

1-

beta

, mR

NA

sequ

ence

TC

A00

6-IQ

225G

_G07

_.b_

13.a

b1

Tc00

.104

7053

5041

31.1

0 H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l N

ull

Nul

l

(pse

udog

ene)

TCA

006-

IQ22

5G_G

09_.

b_13

.ab1

Tc

00.1

0470

5350

9695

.150

K

ines

in, p

utat

ive

Nul

l N

ull

Nul

l N

ull

TC

A00

6-IQ

225G

_G10

_.b_

14.a

b1

Tc00

.104

7053

5068

43.2

0 R

etro

trans

poso

n ho

t spo

t pro

tein

N

ull

Nul

l N

ull

Nul

l

(RH

S, p

seud

ogen

e), p

utat

ive

TCA

006-

IQ22

5G_H

01_.

b_15

.ab1

N

ull

Not

iden

tified

N

ull

Nul

l N

ull

Nul

l N

ull

Nul

lTC

A00

6-IQ

225G

_H04

_.b_

16.a

b1

Tc00

.104

7053

5061

55.8

0 H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l N

ull

Nul

l TC

A00

6-IQ

225G

_H12

_.b_

16.a

b1

Nul

l N

ot id

entifi

ed

Nul

l N

ull

Nul

l N

ull

Nul

l N

ull

TCA

007-

IQ23

1A_A

08_.

B_0

2.ab

1 N

ull

Not

iden

tified

N

ull

Nul

l N

ull

Nul

l N

ull

Nul

lTC

A00

7-IQ

231A

_A09

_.B

_01.

ab1

Nul

l N

ot id

entifi

ed

Nul

l N

ull

Nul

l N

ull

Nul

l N

ull

TCA

007-

IQ23

1A_A

12_.

B_0

2.ab

1 Tc

00.1

0470

5351

0877

.160

H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l N

ull

Nul

l TC

A00

7-IQ

231A

_B04

_.B

_04.

ab1

Nul

l N

ot id

entifi

ed

Nul

l N

ull

Nul

l N

ull

Nul

l N

ull

TCA

007-

IQ23

1A_B

08_.

B_0

4.ab

1 Tc

00.1

0470

5351

1115

.10

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

Nul

l N

ull

TC

A00

7-IQ

231A

_D09

_.B

_07.

ab1

Con

tig10

4705

3510

755

Mat

ches

the

3’ e

nd a

nd th

e

Nul

l N

ull

Nul

l N

ull

1047

0535

1075

5

do

wns

tream

flan

king

re

gion

s of t

he g

ene

Tc00

.104

7053

5107

55.1

20TC

A00

7-IQ

231A

_E03

_.B

_09.

ab1

Tc00

.104

7053

5083

69.4

0 Se

rine/

thre

onin

e-pr

otei

n ki

nase

N

ull

Nul

l N

ull

Nul

l

A (p

seud

ogen

e), p

utat

ive

TCA

007-

IQ23

1A_E

09_.

B_0

9.ab

1 N

ull

Not

iden

tified

N

ull

Nul

l N

ull

Nul

l N

ull

Nul

l

Supp

lem

enta

ry M

ater

ial S

1. C

ontin

ued.

Con

tinue

d on

nex

t pag

e

1615


Transcriptome of Trypanosoma cruzi mammalian stagesSu

pple

men

tary

Mat

eria

l S1.

Con

tinue

d.

Con

tinue

d on

nex

t pag

e

Que

ry

Bes

t bla

stn

hit a

gain

st

Ann

otat

ion

Bes

t bla

stn

hit a

gain

st

EST-

stag

e B

est b

last

x hi

t aga

inst

Pr

oteo

me-

stag

e C

ontig

s R

eads

T.

cru

zi g

enes

and

con

tigs

T.

cru

zi E

STs

T.

cru

zi p

rote

ome

TCA

007-

IQ23

1A_F

04_.

B_1

2.ab

1 N

ull

Not

iden

tified

N

ull

Nul

l N

ull

Nul

l N

ull

Nul

lTC

A00

7-IQ

231A

_F06

_.B

_12.

ab1

Tc00

.104

7053

5110

37.4

0 H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l N

ull

Nul

l

TCA

007-

IQ23

1A_F

07_.

B_1

1.ab

1 Tc

00.1

0470

5350

3955

.100

Pr

otei

n ki

nase

, put

ativ

e N

ull

Nul

l N

ull

Nul

l

TCA

007-

IQ23

1A_G

06_.

B_1

4.ab

1 Tc

00.1

0470

5351

0149

.50

DN

A re

pair

helic

ase

and

N

ull

Nul

l N

ull

Nul

l

trans

crip

tion

fact

or

prot

ein,

put

ativ

eTC

A00

7-IQ

231A

_H03

_.B

_15.

ab1

Nul

l N

ot id

entifi

ed

Nul

l N

ull

Nul

l N

ull

Nul

l N

ull

TCA

007-

IQ23

1A_H

07_.

B_1

5.ab

1 Tc

00.1

0470

5350

5789

.20

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

Nul

l N

ull

TC

A00

7-IQ

231A

_H10

_.B

_16.

ab1

Tc00

.104

7053

5103

11.4

0 H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l N

ull

Nul

l

TCA

007-

IQ23

1B_A

05_.

B_0

1.ab

1 N

ull

Not

iden

tified

N

ull

Nul

l N

ull

Nul

l N

ull

Nul

lTC

A00

7-IQ

231B

_A06

_.B

_02.

ab1

Nul

l N

ot id

entifi

ed

Nul

l N

ull

Nul

l N

ull

Nul

l N

ull

TCA

007-

IQ23

1B_A

07_.

B_0

1.ab

1 Tc

00.1

0470

5350

8811

.10

Hyp

othe

tical

pro

tein

N

ull

Nul

l N

ull

Nul

l

TCA

007-

IQ23

1B_B

04_.

B_0

4.ab

1 Tc

00.1

0470

5351

0077

.20

Tran

s-si

alid

ase

(pse

udog

ene)

, N

ull

Nul

l N

ull

Nul

l

puta

tive

TCA

007-

IQ23

1B_B

05_.

B_0

3.ab

1 N

ull

Not

iden

tified

N

ull

Nul

l N

ull

Nul

l N

ull

Nul

lTC

A00

7-IQ

231B

_B06

_.B

_04.

ab1

Nul

l N

ot id

entifi

ed

Nul

l N

ull

Nul

l N

ull

Nul

l N

ull

TCA

007-

IQ23

1B_C

02_.

B_0

6.ab

1 Tc

00.1

0470

5351

0297

.110

H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l N

ull

Nul

l

TCA

007-

IQ23

1B_C

05_.

B_0

5.ab

1 N

ull

Not

iden

tified

N

ull

Nul

l N

ull

Nul

l N

ull

Nul

lTC

A00

7-IQ

231B

_C06

_.B

_06.

ab1

Nul

l N

ot id

entifi

ed

Nul

l N

ull

Nul

l N

ull

Nul

l N

ull

TCA

007-

IQ23

1B_D

04_.

B_0

8.ab

1 Tc

00.1

0470

5350

7093

.260

A

BC

tran

spor

ter,

puta

tive

Nul

l N

ull

Nul

l N

ull

TC

A00

7-IQ

231B

_D05

_.B

_07.

ab1

Nul

l N

ot id

entifi

ed

Nul

l N

ull

Nul

l N

ull

Nul

l N

ull

TCA

007-

IQ23

1B_D

06_.

B_0

8.ab

1 N

ull

Not

iden

tified

N

ull

Nul

l N

ull

Nul

l N

ull

Nul

lTC

A00

7-IQ

231B

_E05

_.B

_09.

ab1

Nul

l N

ot id

entifi

ed

Nul

l N

ull

Nul

l N

ull

Nul

l N

ull

TCA

007-

IQ23

1B_F

05_.

B_1

1.ab

1 N

ull

Not

iden

tified

N

ull

Nul

l N

ull

Nul

l N

ull

Nul

lTC

A00

7-IQ

231B

_F06

_.B

_12.

ab1

Nul

l N

ot id

entifi

ed

Nul

l N

ull

Nul

l N

ull

Nul

l N

ull

TCA

007-

IQ23

1B_F

11_.

B_1

1.ab

1 Tc

00.1

0470

5351

1365

.90

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

Nul

l N

ull

TC

A00

7-IQ

231B

_F12

_.B

_12.

ab1

Nul

l N

ot id

entifi

ed

Nul

l N

ull

Nul

l N

ull

Nul

l N

ull

TCA

007-

IQ23

1B_G

05_.

B_1

3.ab

1 N

ull

Not

iden

tified

N

ull

Nul

l N

ull

Nul

l N

ull

Nul

lTC

A00

7-IQ

231B

_G06

_.B

_14.

ab1

Nul

l N

ot id

entifi

ed

Nul

l N

ull

Nul

l N

ull

Nul

l N

ull

TCA

007-

IQ23

1B_G

07_.

B_1

3.ab

1 N

ull

Not

iden

tified

N

ull

Nul

l N

ull

Nul

l N

ull

Nul

lTC

A00

7-IQ

231B

_G09

_.B

_13.

ab1

Nul

l N

ot id

entifi

ed

Nul

l N

ull

Nul

l N

ull

Nul

l N

ull

TCA

007-

IQ23

1B_H

05_.

B_1

5.ab

1 N

ull

Not

iden

tified

N

ull

Nul

l N

ull

Nul

l N

ull

Nul

lTC

A00

7-IQ

231B

_H06

_.B

_16.

ab1

Nul

l N

ot id

entifi

ed

Nul

l N

ull

Nul

l N

ull

Nul

l N

ull

TCA

007-

IQ23

1B_H

10_.

B_1

6.ab

1 Tc

00.1

0470

5350

8111

.40

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

Nul

l N

ull

TC

A00

8-IQ

229A

_A06

_.B

_02.

ab1

Tc00

.104

7053

5088

11.3

0 H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l N

ull

Nul

l

TCA

008-

IQ22

9A_B

05_.

B_0

3.ab

1 Tc

00.1

0470

5351

0285

.60

Ubi

quin

one

bios

ynth

esis

N

ull

Nul

l N

ull

Nul

l

met

hyltr

ansf

eras

e, p

utat

ive

1616


C. Martins et al.

Que

ry

Bes

t bla

stn

hit a

gain

st

Ann

otat

ion

Bes

t bla

stn

hit a

gain

st

EST-

stag

e B

est b

last

x hi

t aga

inst

Pr

oteo

me-

stag

e C

ontig

s R

eads

T.

cru

zi g

enes

and

con

tigs

T.

cru

zi E

STs

T.

cru

zi p

rote

ome

TCA

008-

IQ22

9A_B

06_.

B_0

4.ab

1 Tc

00.1

0470

5350

6247

.160

H

ypot

hetic

al p

rote

in, c

onse

rved

TE

NU

3645

T. c

ruzi

epi

mas

tigot

e

Epim

astig

ote

Nul

l N

ull

norm

aliz

ed c

DN

A li

brar

y T.

cru

zi

cDN

A c

lone

29l

21 5

',

mR

NA

sequ

ence

TCA

008-

IQ22

9A_B

12_.

B_0

4.ab

1 Tc

00.1

0470

5351

1533

.10

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

Nul

l N

ull

TC

A00

8-IQ

229A

_C11

_.B

_05.

ab1

Tc00

.104

7053

5063

21.2

80

Hyp

othe

tical

pro

tein

, con

serv

ed

TEN

U38

97 T

. cru

zi e

pim

astig

ote

Ep

imas

tigot

e N

ull

Nul

l

no

rmal

ized

cD

NA

libr

ary

T. c

ruzi

cD

NA

clo

ne 4

2g4

5',

m

RN

A se

quen

ce

TCA

008-

IQ22

9A_D

12_.

B_0

8.ab

1 Tc

00.1

0470

5350

6559

.559

A

ntig

enic

pro

tein

, put

ativ

e N

ull

Nul

l N

ull

Nul

l

TCA

008-

IQ22

9A_F

07_.

B_1

1.ab

1 N

ull

Not

iden

tified

N

ull

Nul

l N

ull

Nul

l N

ull

Nul

lTC

A00

8-IQ

229A

_F08

_.B

_12.

ab1

Tc00

.104

7053

5110

71.2

02

Hyp

othe

tical

pro

tein

, con

serv

ed

TcTR

-113

3 Tc

TR T

. cru

zi

Tryp

omas

tigot

e N

ull

Nul

l N

ull

Nul

l

cDN

A c

lone

09k

20 5

',

mR

NA

sequ

ence

TCA

008-

IQ22

9A_F

09_.

B_1

1.ab

1 N

ull

Not

iden

tified

N

ull

Nul

l N

ull

Nul

l N

ull

Nul

lTC

A00

8-IQ

229A

_F10

_.B

_12.

ab1

Nul

l N

ot id

entifi

ed

Nul

l N

ull

Nul

l N

ull

Nul

l N

ull

TCA

008-

IQ22

9A_F

12_.

B_1

2.ab

1 Tc

00.1

0470

5350

6885

.270

Tu

bulin

tyro

sine

liga

se, p

utat

ive

Nul

l N

ull

Nul

l N

ull

TC

A00

8-IQ

229A

_G02

_.B

_14.

ab1

Nul

l N

ot id

entifi

ed

Nul

l N

ull

Nul

l N

ull

Nul

l N

ull

TCA

008-

IQ22

9A_G

03_.

B_1

3.ab

1 N

ull

Not

iden

tified

N

ull

Nul

l N

ull

Nul

l N

ull

Nul

lTC

A00

8-IQ

229A

_G04

_.B

_14.

ab1

Nul

l N

ot id

entifi

ed

Nul

l N

ull

Nul

l N

ull

Nul

l N

ull

TCA

008-

IQ22

9A_G

05_.

B_1

3.ab

1 N

ull

Not

iden

tified

N

ull

Nul

l N

ull

Nul

l N

ull

Nul

lTC

A00

8-IQ

229A

_G06

_.B

_14.

ab1

Nul

l N

ot id

entifi

ed

Nul

l N

ull

Nul

l N

ull

Nul

l N

ull

TCA

008-

IQ22

9A_G

07_.

B_1

3.ab

1 N

ull

Not

iden

tified

N

ull

Nul

l N

ull

Nul

l N

ull

Nul

lTC

A00

8-IQ

229A

_G10

_.B

_14.

ab1

Tc00

.104

7053

5112

83.2

80

Prot

ein

kina

se, p

utat

ive

Nul

l N

ull

Nul

l N

ull

TC

A00

8-IQ

229A

_H03

_.B

_15.

ab1

Nul

l N

ot id

entifi

ed

Nul

l N

ull

Nul

l N

ull

Nul

l N

ull

TCA

008-

IQ22

9B_A

06_.

B_0

2.ab

1 Tc

00.1

0470

5350

6941

.90

ATP-

depe

nden

t DEA

D/H

DN

A

Nul

l N

ull

Nul

l N

ull

he

licas

e re

cQ fa

mily

, put

ativ

eTC

A00

8-IQ

229B

_A09

_.B

_01.

ab1

Tc00

.104

7053

5065

59.3

60

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

Nul

l N

ull

TC

A00

8-IQ

229B

_A12

_.B

_02.

ab1

Nul

l N

ot id

entifi

ed

Nul

l N

ull

Nul

l N

ull

Nul

l N

ull

TCA

008-

IQ22

9B_B

05_.

B_0

3.ab

1 86

20.te

0000

5 D

IRE

Nul

l N

ull

Nul

l N

ull

TCA

008-

IQ22

9B_C

02_.

B_0

6.ab

1 56

13.te

0000

5 SI

RE

TEN

U24

24 T

. cru

zi e

pim

astig

ote

Ep

imas

tigot

e N

ull

Nul

l

no

rmal

ized

cD

NA

libr

ary

T. c

ruzi

cDN

A c

lone

26b

10 5

’ sim

ilar t

o

T. c

ruzi

H2A

gen

e fo

r his

tone

H2A

em

b|X

6728

7|TC

HIS

H2A

,

mR

NA

sequ

ence

TC

A00

8-IQ

229B

_C09

_.B

_05.

ab1

Tc00

.104

7053

5114

67.3

0 H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l N

ull

Nul

l

Supp

lem

enta

ry M

ater

ial S

1. C

ontin

ued.

Con

tinue

d on

nex

t pag

e

1617



Que

ry

Bes

t bla

stn

hit a

gain

st

Ann

otat

ion

Bes

t bla

stn

hit a

gain

st

EST-

stag

e B

est b

last

x hi

t aga

inst

Pr

oteo

me-

stag

e C

ontig

s R

eads

T.

cru

zi g

enes

and

con

tigs

T.

cru

zi E

STs

T.

cru

zi p

rote

ome

TCA

008-

IQ22

9B_C

10_.

B_0

6.ab

1 Tc

00.1

0470

5350

6825

.219

H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l N

ull

Nul

l

TCA

008-

IQ22

9B_C

12_.

B_0

6.ab

1 Tc

00.1

0470

5350

6773

.130

Pu

mili

o-re

peat

, RN

A-b

indi

ng

Nul

l N

ull

Nul

l N

ull

pr

otei

n, p

utat

ive

TCA

008-

IQ22

9B_D

07_.

B_0

7.ab

1 N

ull

Not

iden

tified

N

ull

Nul

l N

ull

Nul

l N

ull

Nul

lTC

A00

8-IQ

229B

_F01

_.B

_11.

ab1

Tc00

.104

7053

5114

27.1

9 H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l N

ull

Nul

l

TCA

008-

IQ22

9B_F

03_.

B_1

1.ab

1 Tc

00.1

0470

5350

4153

.370

H

ypot

hetic

al p

rote

in

Nul

l N

ull

Nul

l N

ull

TC

A00

8-IQ

229B

_F11

_.B

_11.

ab1

Tc00

.104

7053

5067

29.9

0 H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l N

ull

Nul

l

TCA

008-

IQ22

9B_G

01_.

B_1

3.ab

1 Tc

00.1

0470

5350

9891

.70

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

Nul

l N

ull

(p

seud

ogen

e)TC

A00

8-IQ

229B

_G06

_.B

_14.

ab1

Tc00

.104

7053

5089

53.1

0 H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l N

ull

Nul

l

TCA

008-

IQ22

9B_H

03_.

B_1

5.ab

1 Tc

00.1

0470

5350

7211

.40

Inos

ine-

5'-m

onop

hosp

hate

N

ull

Nul

l N

ull

Nul

l

dehy

drog

enas

e, p

utat

ive

TCA

008-

IQ22

9B_H

12_.

B_1

6.ab

1 N

ull

Not

iden

tified

N

ull

Nul

l N

ull

Nul

l N

ull

Nul

lTC

A00

9-IQ

230A

_A05

_.B

_01.

ab1

Nul

l N

ot id

entifi

ed

Nul

l N

ull

Nul

l N

ull

Nul

l N

ull

TCA

009-

IQ23

0A_A

07_.

B_0

1.ab

1 N

ull

Not

iden

tified

N

ull

Nul

l N

ull

Nul

l N

ull

Nul

lTC

A00

9-IQ

230A

_A08

_.B

_02.

ab1

Nul

l N

ot id

entifi

ed

Nul

l N

ull

Nul

l N

ull

Nul

l N

ull

TCA

009-

IQ23

0A_A

09_.

B_0

1.ab

1 Tc

00.1

0470

5350

8739

.40

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

Nul

l N

ull

TC

A00

9-IQ

230A

_B07

_.B

_03.

ab1

Nul

l N

ot id

entifi

ed

Nul

l N

ull

Nul

l N

ull

Nul

l N

ull

TCA

009-

IQ23

0A_B

08_.

B_0

4.ab

1 N

ull

Not

iden

tified

N

ull

Nul

l N

ull

Nul

l N

ull

Nul

lTC

A00

9-IQ

230A

_B12

_.B

_04.

ab1

Tc00

.104

7053

5076

81.2

00

Serin

e ca

rbox

ypep

tidas

e

Nul

l N

ull

Nul

l N

ull

S2

8, p

utat

ive

TCA

009-

IQ23

0A_C

04_.

B_0

6.ab

1 Tc

00.1

0470

5350

4097

.10

RN

A e

ditin

g co

mpl

ex

Nul

l N

ull

Nul

l N

ull

pr

otei

n M

P61,

put

ativ

eTC

A00

9-IQ

230A

_C07

_.B

_05.

ab1

Nul

l N

ot id

entifi

ed

Nul

l N

ull

Nul

l N

ull

Nul

l N

ull

TCA

009-

IQ23

0A_D

05_.

B_0

7.ab

1 Tc

00.1

0470

5350

6961

.150

Tr

ans-

sial

idas

e, p

utat

ive

Nul

l N

ull

Nul

l N

ull

TC

A00

9-IQ

230A

_D06

_.B

_08.

ab1

Tc00

.104

7053

5040

47.5

0 H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l N

ull

Nul

l

TCA

009-

IQ23

0A_D

07_.

B_0

7.ab

1 N

ull

Not

iden

tified

N

ull

Nul

l N

ull

Nul

l N

ull

Nul

lTC

A00

9-IQ

230A

_D08

_.B

_08.

ab1

Tc00

.104

7053

5078

17.6

0 H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l N

ull

Nul

l

TCA

009-

IQ23

0A_E

07_.

B_0

9.ab

1 N

ull

Not

iden

tified

N

ull

Nul

l N

ull

Nul

l N

ull

Nul

lTC

A00

9-IQ

230A

_F03

_.B

_11.

ab1

Tc00

.104

7053

5070

35.8

0 Tr

ans-

sial

idas

e

Nul

l N

ull

62_T

rypo

Tr

ypom

astig

ote

(p

seud

ogen

e), p

utat

ive

TCA

009-

IQ23

0A_F

04_.

B_1

2.ab

1 N

ull

Not

iden

tified

N

ull

Nul

l N

ull

Nul

l N

ull

Nul

lTC

A00

9-IQ

230A

_F07

_.B

_11.

ab1

Nul

l N

ot id

entifi

ed

Nul

l N

ull

Nul

l N

ull

Nul

l N

ull

TCA

009-

IQ23

0A_G

07_.

B_1

3.ab

1 N

ull

Not

iden

tified

N

ull

Nul

l N

ull

Nul

l N

ull

Nul

lTC

A00

9-IQ

230A

_G08

_.B

_14.

ab1

Nul

l N

ot id

entifi

ed

Nul

l N

ull

Nul

l N

ull

Nul

l N

ull

TCA

009-

IQ23

0A_H

07_.

B_1

5.ab

1 N

ull

Not

iden

tified

N

ull

Nul

l N

ull

Nul

l N

ull

Nul

lTC

A00

9-IQ

230B

_A01

_.B

_01.

ab1

Nul

l N

ot id

entifi

ed

Nul

l N

ull

Nul

l N

ull

Nul

l N

ull

Supp

lem

enta

ry M

ater

ial S

1. C

ontin

ued.

Con

tinue

d on

nex

t pag

e

1618


C. Martins et al.

Supp

lem

enta

ry M

ater

ial S

1. C

ontin

ued.

Con

tinue

d on

nex

t pag

e

Que

ry

Bes

t bla

stn

hit a

gain

st

Ann

otat

ion

Bes

t bla

stn

hit a

gain

st

EST-

stag

e B

est b

last

x hi

t aga

inst

Pr

oteo

me-

stag

e C

ontig

s R

eads

T.

cru

zi g

enes

and

con

tigs

T.

cru

zi E

STs

T.

cru

zi p

rote

ome

TCA

009-

IQ23

0B_A

06_.

B_0

2.ab

1 N

ull

Not

iden

tified

N

ull

Nul

l N

ull

Nul

l N

ull

Nul

lTC

A00

9-IQ

230B

_A08

_.B

_02.

ab1

Tc00

.104

7053

5109

57.9

C

alpa

in-li

ke c

yste

ine

Tc

TR-4

65 T

cTR

T. c

ruzi

Tr

ypom

astig

ote

Nul

l N

ull

pe

ptid

ase,

put

ativ

e cD

NA

clo

ne 0

2p18

5',

m

RN

A se

quen

ce

TCA

009-

IQ23

0B_A

12_.

B_0

2.ab

1 Tc

00.1

0470

5351

1633

.79

Mic

rotu

bule

-ass

ocia

ted

EA-2

-1 T

. cru

zi d

iffer

entia

l N

ot sp

ecifi

ed

Nul

l N

ull

pr

otei

n, p

utat

ive

disp

lay

cDN

A li

brar

y T.

cru

zi

cDN

A, m

RN

A se

quen

ce

TCA

009-

IQ23

0B_B

01_.

B_0

3.ab

1 N

ull

Not

iden

tified

N

ull

Nul

l N

ull

Nul

l N

ull

Nul

lTC

A00

9-IQ

230B

_B05

_.B

_03.

ab1

Tc00

.104

7053

5095

81.1

0 Tr

ans-

sial

idas

e, p

utat

ive

Nul

l N

ull

Nul

l N

ull

TC

A00

9-IQ

230B

_C08

_.B

_06.

ab1

Tc00

.104

7053

5085

69.8

0 Ph

osph

oace

tylg

luco

sam

ine

N

ull

Nul

l N

ull

Nul

l

mut

ase,

put

ativ

eTC

A00

9-IQ

230B

_C09

_.B

_05.

ab1

Tc00

.104

7053

5074

83.8

0 H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l N

ull

Nul

l

TCA

009-

IQ23

0B_D

02_.

B_0

8.ab

1 N

ull

Not

iden

tified

N

ull

Nul

l N

ull

Nul

l N

ull

Nul

lTC

A00

9-IQ

230B

_D04

_.B

_08.

ab1

Nul

l N

ot id

entifi

ed

Nul

l N

ull

Nul

l N

ull

Nul

l N

ull

TCA

009-

IQ23

0B_D

05_.

B_0

7.ab

1 Tc

00.1

0470

5350

3697

.70

Hyp

othe

tical

pro

tein

, con

serv

ed

TEN

Q08

90 T

. cru

zi

Epim

astig

ote

184_

Am

a.m

eta

Am

astig

ote,

ep

imas

tigot

e no

rmal

ized

m

etac

yclic

cD

NA

libr

ary

T. c

ruzi

cDN

A, m

RN

A se

quen

ce

TCA

009-

IQ23

0B_D

06_.

B_0

8.ab

1 N

ull

Not

iden

tified

N

ull

Nul

l N

ull

Nul

l N

ull

Nul

lTC

A00

9-IQ

230B

_D11

_.B

_07.

ab1

Tc00

.104

7053

5111

17.1

0 R

etro

trans

poso

n ho

t spo

t pro

tein

am

astc

-117

4 Tc

AM

T. c

ruzi

A

mas

tigot

e 34

_Met

a M

etac

yclic

(RH

S, p

seud

ogen

e), p

utat

ive

cDN

A c

lone

9C

12 5

',

mR

NA

sequ

ence

TC

A00

9-IQ

230B

_E09

_.B

_09.

ab1

Tc00

.104

7053

5118

73.5

H

ypot

hetic

al p

rote

in

Nul

l N

ull

Nul

l N

ull

TC

A00

9-IQ

230B

_E10

_.B

_10.

ab1

Tc00

.104

7053

5106

45.4

0 H

ypot

hetic

al p

rote

in,

Nul

l N

ull

Nul

l N

ull

co

nser

ved

(pse

udog

ene)

TCA

009-

IQ23

0B_F

04_.

B_1

2.ab

1 Tc

00.1

0470

5350

6155

.60

Ald

ehyd

e de

hydr

ogen

ase,

put

ativ

e N

ull

Nul

l N

ull

Nul

l

TCA

009-

IQ23

0B_G

02_.

B_1

4.ab

1 Tc

00.1

0470

5350

8321

.40

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

Nul

l N

ull

TC

A00

9-IQ

230B

_G09

_.B

_13.

ab1

Con

tig10

4705

3508

827

Mat

ches

the

inte

r-cod

ing

TE

NU

1696

T. c

ruzi

epi

mas

tigot

e Ep

imas

tigot

e N

ull

Nul

l 10

4705

3508

827

regi

on o

f the

gen

es

norm

aliz

ed c

DN

A li

brar

y

Tc

00.1

0470

5350

8827

.10

and

T.

cru

zi c

DN

A c

lone

20j

13 3

’,

Tc

00.1

0470

5350

8827

.20

mR

NA

sequ

ence

TCA

009-

IQ23

0C_A

07_.

B_0

1.ab

1 Tc

00.1

0470

5351

0955

.4

Lipa

se-li

ke p

rote

in, p

utat

ive

Nul

l N

ull

Nul

l N

ull

TC

A00

9-IQ

230C

_B04

_.B

_04.

ab1

Tc00

.104

7053

5104

07.7

0 H

ypot

hetic

al p

rote

in

Nul

l N

ull

Nul

l N

ull

1619



Que

ry

Bes

t bla

stn

hit a

gain

st

Ann

otat

ion

Bes

t bla

stn

hit a

gain

st

EST-

stag

e B

est b

last

x hi

t aga

inst

Pr

oteo

me-

stag

e C

ontig

s R

eads

T.

cru

zi g

enes

and

con

tigs

T.

cru

zi E

STs

T.

cru

zi p

rote

ome

TCA

009-

IQ23

0C_C

04_.

B_0

6.ab

1 11

843.

rrna

0000

3 R

NA

ribo

som

al

TEN

U32

27 T

. cru

zi e

pim

astig

ote

Ep

imas

tigot

e N

ull

Nul

l

no

rmal

ized

cD

NA

libr

ary

T.

cru

zi c

DN

A c

lone

29o

3

5' si

mila

r to

T. c

ruzi

5.8

S

ribos

omal

RN

A, i

nter

nal

tra

nscr

ibed

spac

ers

1-

7 (I

TS1-

ITS7

), an

d

28S

ribos

omal

RN

A

gb

|L22

334|

TRB

S3R

RB

N,

m

RN

A se

quen

ceTC

A00

9-IQ

230C

_D08

_.B

_08.

ab1

Tc00

.104

7053

5092

05.1

20

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

Nul

l N

ull

TC

A00

9-IQ

230C

_E04

_.B

_10.

ab1

Tc00

.104

7053

5115

85.1

0 H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l N

ull

Nul

l

TCA

009-

IQ23

0C_F

10_.

B_1

2.ab

1 22

080.

rrna

0000

1 R

NA

ribo

som

al

TEN

F068

2 T.

cru

zi e

pim

astig

ote

Ep

imas

tigot

e N

ull

Nul

l

no

rmal

ized

cD

NA

libr

ary

T.

cru

zi c

DN

A c

lone

682

5',

m

RN

A se

quen

ceTC

A00

9-IQ

230D

_A02

_.B

_02.

ab1

Tc00

.104

7053

5104

41.2

0 D

ispe

rsed

gen

e fa

mily

pro

tein

N

ull

Nul

l N

ull

Nul

l

1 (D

GF-

1), p

utat

ive

TCA

009-

IQ23

0D_A

12_.

B_0

2.ab

1 N

ull

195-

bp sa

telli

te D

NA

N

ull

Nul

l N

ull

Nul

l

TCA

009-

IQ23

0D_B

01_.

B_0

3.ab

1 N

ull

Not

iden

tified

N

ull

Nul

l N

ull

Nul

l N

ull

Nul

lTC

A00

9-IQ

230D

_B05

_.B

_03.

ab1

Tc00

.104

7053

5076

11.1

99

Dis

pers

ed g

ene

fam

ily p

rote

in

Nul

l N

ull

Nul

l N

ull

1

(DG

F-1)

, put

ativ

eTC

A00

9-IQ

230D

_C12

_.B

_06.

ab1

Nul

l N

ot id

entifi

ed

Nul

l N

ull

Nul

l N

ull

Nul

l N

ull

TCA

009-

IQ23

0D_D

10_.

B_0

8.ab

1 N

ull

195-

bp sa

telli

te D

NA

TE

NU

4403

T. c

ruzi

epi

mas

tigot

e

Epim

astig

ote

Nul

l N

ull

norm

aliz

ed c

DN

A li

brar

y

T. c

ruzi

cD

NA

clo

ne 5

h21

3',

m

RN

A se

quen

ceTC

A00

9-IQ

230D

_F11

_.B

_11.

ab1

Tc00

.104

7053

5101

21.9

0 H

ypot

hetic

al p

rote

in, c

onse

rved

TE

NU

3409

T. c

ruzi

epi

mas

tigot

e

Epim

astig

ote

Nul

l N

ull

norm

aliz

ed c

DN

A li

brar

y

T. c

ruzi

cD

NA

clo

ne 2

9b3

5',

m

RN

A se

quen

ceTC

A00

9-IQ

230D

_G03

_.B

_13.

ab1

Tc00

.104

7053

5041

53.9

0 D

ynei

n he

avy

chai

n

Nul

l N

ull

Nul

l N

ull

(p

seud

ogen

e), p

utat

ive

TCA

009-

IQ23

0E_A

01_.

B_0

1.ab

1 N

ull

Not

iden

tified

N

ull

Nul

l N

ull

Nul

l N

ull

Nul

l

Con

tinue

d on

nex

t pag

e

Supp

lem

enta

ry M

ater

ial S

1. C

ontin

ued.

1620


C. Martins et al.

Que

ry

Bes

t bla

stn

hit a

gain

st

Ann

otat

ion

Bes

t bla

stn

hit a

gain

st

EST-

stag

e B

est b

last

x hi

t aga

inst

Pr

oteo

me-

stag

e C

ontig

s R

eads

T.

cru

zi g

enes

and

con

tigs

T.

cru

zi E

STs

T.

cru

zi p

rote

ome

TCA

009-

IQ23

0E_A

04_.

B_0

2.ab

1 Tc

00.1

0470

5350

8869

.10

Hyp

othe

tical

pro

tein

TE

NU

3457

T. c

ruzi

epi

mas

tigot

e

Epim

astig

ote

Nul

l N

ull

norm

aliz

ed c

DN

A li

brar

y

T. c

ruzi

cD

NA

clo

ne 2

9g24

5' si

mila

r to

T. c

ruzi

85

kD

su

rfac

e an

tigen

(gp8

5)

gb

|M64

836|

TRB

85K

D,

m

RN

A se

quen

ceTC

A00

9-IQ

230E

_A06

_.B

_02.

ab1

Nul

l N

ot id

entifi

ed

Nul

l N

ull

Nul

l N

ull

Nul

l N

ull

TCA

009-

IQ23

0E_A

07_.

B_0

1.ab

1 Tc

00.1

0470

5350

7641

.14

Neu

robe

achi

n/be

ige

N

ull

Nul

l N

ull

Nul

l

pr

otei

n, p

utat

ive

TCA

009-

IQ23

0E_A

08_.

B_0

2.ab

1 N

ull

Not

iden

tified

N

ull

Nul

l N

ull

Nul

l N

ull

Nul

lTC

A00

9-IQ

230E

_A09

_.B

_01.

ab1

Nul

l N

ot id

entifi

ed

Nul

l N

ull

Nul

l N

ull

Nul

l N

ull

TCA

009-

IQ23

0E_A

12_.

B_0

2.ab

1 N

ull

Not

iden

tified

N

ull

Nul

l N

ull

Nul

l N

ull

Nul

lTC

A00

9-IQ

230E

_B01

_.B

_03.

ab1

Nul

l N

ot id

entifi

ed

Nul

l N

ull

Nul

l N

ull

Nul

l N

ull

TCA

009-

IQ23

0E_B

05_.

B_0

3.ab

1 N

ull

Not

iden

tified

N

ull

Nul

l N

ull

Nul

l N

ull

Nul

lTC

A00

9-IQ

230E

_B10

_.B

_04.

ab1

264.

rrna

0000

2 R

NA

ribo

som

al

Nul

l N

ull

106_

Tryp

o Tr

ypom

astig

ote

TC

A00

9-IQ

230E

_B12

_.B

_04.

ab1

Tc00

.104

7053

5116

57.3

0 H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l N

ull

Nul

l

TCA

009-

IQ23

0E_C

04_.

B_0

6.ab

1 Tc

00.1

0470

5350

6367

.170

H

ypot

hetic

al p

rote

in

Nul

l N

ull

Nul

l N

ull

TC

A00

9-IQ

230E

_C11

_.B

_05.

ab1

Nul

l N

ot id

entifi

ed

Nul

l N

ull

Nul

l N

ull

Nul

l N

ull

TCA

009-

IQ23

0E_C

12_.

B_0

6.ab

1 Tc

00.1

0470

5351

1071

.202

H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l N

ull

Nul

l

TCA

009-

IQ23

0E_D

12_.

B_0

8.ab

1 N

ull

Not

iden

tified

N

ull

Nul

l N

ull

Nul

l N

ull

Nul

lTC

A00

9-IQ

230E

_E03

_.B

_09.

ab1

Tc00

.104

7053

5091

05.1

40

Hea

t sho

ck p

rote

in 8

5, p

utat

ive

amas

tc-3

62 T

cAM

T. c

ruzi

A

mas

tigot

e

497_

Am

a.m

eta.

epi

Am

astig

ote,

cDN

A c

lone

14B

10 5

',

met

acyc

lic,

mR

NA

sequ

ence

ep

imas

tigot

e

TCA

009-

IQ23

0E_E

12_.

B_1

0.ab

1 N

ull

Not

iden

tified

N

ull

Nul

l N

ull

Nul

l N

ull

Nul

lTC

A00

9-IQ

230E

_F02

_.B

_12.

ab1

Tc00

.104

7053

5061

77.5

0 H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l N

ull

Nul

l

TCA

009-

IQ23

0E_F

09_.

B_1

1.ab

1 Tc

00.1

0470

5351

0533

.10

Dyn

ein

heav

y ch

ain,

N

ull

Nul

l N

ull

Nul

l

cyto

solic

, put

ativ

eTC

A00

9-IQ

230E

_G03

_.B

_13.

ab1

Tc00

.104

7053

5105

65.1

79

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

Nul

l N

ull

TC

A00

9-IQ

230E

_G09

_.B

_13.

ab1

Nul

l N

ot id

entifi

ed

Nul

l N

ull

Nul

l N

ull

Nul

l N

ull

TCA

009-

IQ23

0E_G

10_.

B_1

4.ab

1 Tc

00.1

0470

5351

1277

.400

U

DP-

gala

ctos

e

Nul

l N

ull

Nul

l N

ull

tra

nspo

rter,

puta

tive

TCA

009-

IQ23

0E_G

12_.

B_1

4.ab

1 Tc

00.1

0470

5350

6579

.40

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

Nul

l N

ull

TC

A00

9-IQ

230E

_H01

_.B

_15.

ab1

Tc00

.104

7053

5074

29.6

0 H

ypot

hetic

al p

rote

in

Nul

l N

ull

Nul

l N

ull

TC

A00

9-IQ

230E

_H02

_.B

_16.

ab1

Tc00

.104

7053

5094

73.1

0 H

ypot

hetic

al p

rote

in (p

seud

ogen

e)

Nul

l N

ull

Nul

l N

ull

TC

A23

6-IQ

001_

A01

_.B

_01.

ab1

Nul

l N

ot id

entifi

ed

Nul

l N

ull

Nul

l N

ull

Nul

l N

ull

Supp

lem

enta

ry M

ater

ial S

1. C

ontin

ued.

Con

tinue

d on

nex

t pag

e

1621



Que

ry

Bes

t bla

stn

hit a

gain

st

Ann

otat

ion

Bes

t bla

stn

hit a

gain

st

EST-

stag

e B

est b

last

x hi

t aga

inst

Pr

oteo

me-

stag

e C

ontig

s R

eads

T.

cru

zi g

enes

and

con

tigs

T.

cru

zi E

STs

T.

cru

zi p

rote

ome

TCA

236-

IQ00

1_A

02_.

B_0

2.ab

1 Tc

00.1

0470

5350

6279

.220

M

ucin

-ass

ocia

ted

surf

ace

prot

ein

N

ull

Nul

l N

ull

Nul

l

(MA

SP, p

seud

ogen

e), p

utat

ive

TCA

236-

IQ00

1_A

07_.

B_0

1.ab

1 Tc

00.1

0470

5351

0187

.551

C

hape

roni

n H

SP60

mito

chon

dria

l N

ull

Nul

l N

ull

Nul

l

prec

urso

r, pu

tativ

eTC

A23

6-IQ

001_

A09

_.B

_01.

ab1

Tc00

.104

7053

5038

01.9

R

AD

50 D

NA

repa

ir

Nul

l N

ull

Nul

l N

ull

pr

otei

n, p

utat

ive

TCA

236-

IQ00

1_A

12_.

B_0

2.ab

1 N

ull

Not

iden

tified

N

ull

Nul

l N

ull

Nul

l N

ull

Nul

lTC

A23

6-IQ

001_

B04

_.B

_04.

ab1

8054

.te00

005

VIP

ER

Nul

l N

ull

Nul

l N

ull

TC

A23

6-IQ

001_

B06

_.B

_04.

ab1

Nul

l N

ot id

entifi

ed

Nul

l N

ull

Nul

l N

ull

Nul

l N

ull

TCA

236-

IQ00

1_B

11_.

B_0

3.ab

1 Tc

00.1

0470

5350

4153

.270

H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l N

ull

Nul

l

TCA

236-

IQ00

1_C

03_.

B_0

5.ab

1 24

358.

rrna

0000

1 R

NA

ribo

som

al

TEU

F015

4 T.

cru

zi e

pim

astig

ote

Ep

imas

tigot

e N

ull

Nul

l

no

n-no

rmal

ized

cD

NA

libr

ary

T.

cru

zi c

DN

A c

lone

154

5'

si

mila

r to

T. c

ruzi

gen

e fo

r his

tone

H2b

(X60

982)

, mR

NA

sequ

ence

TC

A23

6-IQ

001_

C05

_.B

_05.

ab1

Tc00

.104

7053

5086

71.2

0 Se

rine

carb

oxyp

eptid

ase

N

ull

Nul

l N

ull

Nul

l

(CB

P1),

puta

tive

TCA

236-

IQ00

1_C

07_.

B_0

5.ab

1 Tc

00.1

0470

5350

6503

.53

Hyp

othe

tical

pro

tein

N

ull

Nul

l N

ull

Nul

l

TCA

236-

IQ00

1_D

04_.

B_0

8.ab

1 Tc

00.1

0470

5350

6849

.20

Dyn

ein

heav

y ch

ain

N

ull

Nul

l N

ull

Nul

l

(pse

udog

ene)

, put

ativ

eTC

A23

6-IQ

001_

D05

_.B

_07.

ab1

Tc00

.104

7053

5076

41.1

60

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

Nul

l N

ull

TC

A23

6-IQ

001_

D08

_.B

_08.

ab1

Tc00

.104

7053

5104

99.2

0 H

ypot

hetic

al p

rote

in

Nul

l N

ull

Nul

l N

ull

TC

A23

6-IQ

001_

D09

_.B

_07.

ab1

Tc00

.104

7053

5042

41.8

0 Tr

ans-

sial

idas

e TE

NF0

714

T. c

ruzi

epi

mas

tigot

e

Epim

astig

ote

Nul

l N

ull

(p

seud

ogen

e), p

utat

ive

norm

aliz

ed c

DN

A li

brar

y

T. c

ruzi

cD

NA

clo

ne 7

14 5

',

mR

NA

sequ

ence

TC

A23

6-IQ

001_

D12

_.B

_08.

ab1

Tc00

.104

7053

5115

11.1

0 En

doso

mal

traf

ficki

ng

Nul

l N

ull

Nul

l N

ull

pr

otei

n R

ME-

8, p

utat

ive

TCA

236-

IQ00

1_E1

0_.B

_10.

ab1

Tc00

.104

7053

5114

15.2

1 Tr

ans-

sial

idas

e

Nul

l N

ull

Nul

l N

ull

(p

seud

ogen

e), p

utat

ive

TCA

236-

IQ00

1_E1

2_.B

_10.

ab1

Nul

l N

ot id

entifi

ed

Nul

l N

ull

Nul

l N

ull

Nul

l N

ull

TCA

236-

IQ00

1_F0

3_.B

_11.

ab1

7271

.te00

003

VIP

ER

Nul

l N

ull

Nul

l N

ull

TC

A23

6-IQ

001_

F05_

.B_1

1.ab

1 Tc

00.1

0470

5350

6721

.30

Cal

pain

-like

cys

tein

e

Nul

l N

ull

317_

Met

a.ep

i M

etac

yclic

,

pept

idas

e, p

utat

ive

ep

imas

tigot

eTC

A23

6-IQ

001_

F11_

.B_1

1.ab

1 Tc

00.1

0470

5350

4643

.20

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

Nul

l N

ull

TC

A23

6-IQ

001_

F12_

.B_1

2.ab

1 N

ull

Not

iden

tified

N

ull

Nul

l N

ull

Nul

l N

ull

Nul

l

Supp

lem

enta

ry M

ater

ial S

1. C

ontin

ued.

Con

tinue

d on

nex

t pag

e

1622


C. Martins et al.

Que

ry

Bes

t bla

stn

hit a

gain

st

Ann

otat

ion

Bes

t bla

stn

hit a

gain

st

EST-

stag

e B

est b

last

x hi

t aga

inst

Pr

oteo

me-

stag

e C

ontig

s R

eads

T.

cru

zi g

enes

and

con

tigs

T.

cru

zi E

STs

TCA

236-

IQ00

1_G

03_.

B_1

3.ab

1 Tc

00.1

0470

5350

6847

.50

Tran

s-si

alid

ase

N

ull

Nul

l N

ull

Nul

l

(pse

udog

ene)

, put

ativ

eTC

A23

6-IQ

001_

G04

_.B

_14.

ab1

Tc00

.104

7053

5115

29.8

0 K

inet

opla

st

Nul

l N

ull

187_

Am

a.try

po.m

eta

Am

astig

ote,

D

NA

-ass

ocia

ted

try

pom

astig

ote,

pr

otei

n, p

utat

ive

ep

imas

tigot

e

TCA

236-

IQ00

1_G

06_.

B_1

4.ab

1 Tc

00.1

0470

5350

6505

.30

Hyp

othe

tical

pro

tein

, con

serv

ed

TEN

G03

88 T

. cru

zi

Epim

astig

ote

Nul

l N

ull

epim

astig

ote

norm

alis

ed

cD

NA

libr

ary

T. c

ruzi

cDN

A c

lone

n73

1.r 5

',

mR

NA

sequ

ence

TCA

236-

IQ00

1_G

11_.

B_1

3.ab

1 Tc

00.1

0470

5350

7979

.50

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

Nul

l N

ull

TC

A23

6-IQ

001_

G12

_.B

_14.

ab1

Nul

l N

ot id

entifi

ed

Nul

l N

ull

Nul

l N

ull

Nul

l N

ull

TCA

236-

IQ00

1_H

01_.

B_1

5.ab

1 Tc

00.1

0470

5350

5555

.40

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

Nul

l N

ull

TC

A23

6-IQ

001_

H03

_.B

_15.

ab1

Nul

l N

ot id

entifi

ed

Nul

l N

ull

Nul

l N

ull

Nul

l N

ull

TCA

236-

IQ00

1_H

05_.

B_1

5.ab

1 Tc

00.1

0470

5351

0055

.150

H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l N

ull

Nul

l

TCA

236-

IQ00

1_H

07_.

B_1

5.ab

1 Tc

00.1

0470

5350

6265

.60

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

Nul

l N

ull

TC

A23

6-IQ

001_

H12

_.B

_16.

ab1

Tc00

.104

7053

5115

87.3

0 R

etro

trans

poso

n

Nul

l N

ull

Nul

l N

ull

ho

t spo

t pro

tein

(R

HS,

pse

udog

ene)

, put

ativ

eTC

E006

-IQ

225A

_B01

_.B

_03.

ab1

Tc00

.104

7053

5114

15.1

1 R

etro

trans

poso

n ho

t spo

t N

ull

Nul

l 48

8_M

eta

Met

acyc

lic

(R

HS)

pro

tein

, put

ativ

eTC

E006

-IQ

225A

_B07

_.B

_03.

ab1

Tc00

.104

7053

5083

23.1

99

ATP-

depe

nden

t N

ull

Nul

l N

ull

Nul

l

DEA

D/H

RN

A

helic

ase,

put

ativ

eTC

E006

-IQ

225A

_C07

_.B

_05.

ab1

Tc00

.104

7053

5068

25.1

90

Hyp

othe

tical

pro

tein

TE

NU

2835

T. c

ruzi

Ep

imas

tigot

e N

ull

Nul

l

ep

imas

tigot

e no

rmal

ized

cDN

A li

brar

y T.

cru

zi

cD

NA

clo

ne 2

7d2

5',

m

RN

A se

quen

ce

TCE0

06-I

Q22

5A_C

10_.

B_0

6.ab

1 Tc

00.1

0470

5350

4137

.40

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

Nul

l N

ull

TC

E006

-IQ

225A

_E01

_.B

_09.

ab1

Nul

l N

ot id

entifi

ed

Nul

l N

ull

Nul

l N

ull

Nul

l N

ull

TCE0

06-I

Q22

5A_E

05_.

B_0

9.ab

1 Tc

00.1

0470

5350

6741

.50

Muc

in T

cMU

CII

, put

ativ

e N

ull

Nul

l N

ull

Nul

l

TCE0

06-I

Q22

5A_E

06_.

B_1

0.ab

1 Tc

00.1

0470

5350

8347

.30

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

Nul

l N

ull

TC

E006

-IQ

225A

_F03

_.B

_11.

ab1

Tc00

.104

7053

5098

05.1

00

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

Nul

l N

ull

TC

E006

-IQ

225A

_G03

_.B

_13.

ab1

Tc00

.104

7053

5114

35.1

0 H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l N

ull

Nul

l

TCE0

06-I

Q22

5A_G

07_.

B_1

3.ab

1 N

ull

Not

iden

tified

N

ull

Nul

l N

ull

Nul

l N

ull

Nul

lTC

E006

-IQ

225A

_G12

_.B

_14.

ab1

Nul

l N

ot id

entifi

ed

Nul

l N

ull

Nul

l N

ull

Nul

l N

ull

Supp

lem

enta

ry M

ater

ial S

1. C

ontin

ued.

Con

tinue

d on

nex

t pag

e

1623



Que

ry

Bes

t bla

stn

hit a

gain

st

Ann

otat

ion

Bes

t bla

stn

hit a

gain

st

EST-

stag

e B

est b

last

x hi

t aga

inst

Pr

oteo

me-

stag

e C

ontig

s R

eads

T.

cru

zi g

enes

and

con

tigs

T.

cru

zi E

STs

TCE0

06-I

Q22

5B_A

08_.

B_0

2.ab

1 25

661.

rrna

0000

1 R

NA

ribo

som

al

TEN

Q08

45 T

. cru

zi

Epim

astig

ote

210_

Am

a.m

eta.

epi

Am

astig

ote,

ep

imas

tigot

e no

rmal

ized

m

etac

yclic

,

cD

NA

libr

ary

T. c

ruzi

ep

imas

tigot

e

cDN

A, m

RN

A se

quen

ce

TCE0

06-I

Q22

5B_C

12_.

B_0

6.ab

1 N

ull

Not

iden

tified

N

ull

Nul

l N

ull

Nul

l N

ull

Nul

lTC

E006

-IQ

225B

_E01

_.B

_09.

ab1

Tc00

.104

7053

5100

55.1

00

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

Nul

l N

ull

TC

E006

-IQ

225B

_E05

_.B

_09.

ab1

Tc00

.104

7053

5075

21.1

50

Dis

pers

ed g

ene

fam

ily p

rote

in

Nul

l N

ull

Nul

l N

ull

1

(DG

F-1)

, put

ativ

eTC

E006

-IQ

225B

_F07

_.B

_11.

ab1

Tc00

.104

7053

5092

47.3

0 H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l N

ull

Nul

l

TCE0

06-I

Q22

5B_G

10_.

B_1

4.ab

1 Tc

00.1

0470

5350

3909

.84

Cal

pain

-like

cys

tein

e

Nul

l N

ull

Nul

l N

ull

pe

ptid

ase,

put

ativ

eTC

E006

-IQ

225B

_H04

_.B

_16.

ab1

Tc00

.104

7053

5101

63.6

0 Tr

ans-

sial

idas

e, p

utat

ive

Nul

l N

ull

Nul

l N

ull

TC

E006

-IQ

225B

_H07

_.B

_15.

ab1

Nul

l N

ot id

entifi

ed

Nul

l N

ull

Nul

l N

ull

Nul

l N

ull

TCA

007-

IQ23

1B_E

06_.

B_1

0.ab

1 N

ull

Not

iden

tified

N

ull

Nul

l N

ull

Nul

l N

ull

Nul

l

Supp

lem

enta

ry M

ater

ial S

1. C

ontin

ued.

1624


C. Martins et al.Q

uery

Su

bjec

t A

nnot

atio

n ES

T m

atch

Pr

oteo

me

mat

ch

pfam

_acc

pf

am_i

d pf

am e

-val

ue

Con

tig3

Tc00

.104

7053

5040

39.1

10

Hyp

othe

tical

pro

tein

N

ull

Nul

l

C

ontig

19

Tc00

.104

7053

5104

31.1

90

Hyp

othe

tical

pro

tein

N

ull

Nul

l

C

ontig

24

Tc00

.104

7053

5116

11.1

1 H

ypot

hetic

al p

rote

in

Nul

l N

ull

Con

tig25

Tc

00.1

0470

5350

3975

.20

Hyp

othe

tical

pro

tein

N

ull

Nul

l

C

ontig

115

Tc00

.104

7053

5116

75.3

H

ypot

hetic

al p

rote

in

Nul

l N

ull

PF01

456

Muc

in-li

ke g

lyco

prot

ein

4.8e

-07

Con

tig32

Tc

00.1

0470

5350

9473

.10

Hyp

othe

tical

pro

tein

(pse

udog

ene)

N

ull

Nul

l

C

ontig

12

Tc00

.104

7053

5064

01.2

10

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

Con

tig14

Tc

00.1

0470

5350

4137

.150

H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l PF

0300

6 H

emol

ysin

-III

rela

ted

4.2e

-45

C

ontig

18

Tc00

.104

7053

5099

85.6

0 H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l

C

ontig

20

Tc00

.104

7053

5068

25.6

0 H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l

C

ontig

22

Tc00

.104

7053

5107

59.1

80

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

Con

tig23

Tc

00.1

0470

5350

4929

.5

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

PF00

642

Zinc

fing

er

5.6e

-08

C-x

8-C

-x5-

C-x

3-H

type

C

ontig

35

Tc00

.104

7053

5101

01.3

40

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

C

ontig

38

Tc00

.104

7053

5086

47.2

20

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

Con

tig41

Tc

00.1

0470

5350

7099

.40

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

PF00

622/

PF00

622/

PF00

632

SPRY

dom

ain/

SPRY

9.

3e-1

7/1.

9e-1

7/1.

2e-4

7

do

mai

n/H

ECT-

dom

ain

(ubi

quiti

n-tra

nsfe

rase

)C

ontig

42

Tc00

.104

7053

5112

83.2

20

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

PF08

512

His

tone

cha

pero

ne

1.7e

-33

Rttp

106-

like

Con

tig54

Tc

00.1

0470

5350

9171

.60

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

C

ontig

55

Tc00

.104

7053

5066

49.9

0 H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l C

ontig

58

Tc00

.104

7053

5064

05.1

40

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

PF02

990

Endo

mem

bran

e pr

otei

n 70

2.

4e-1

08C

ontig

59

Tc00

.104

7053

5066

61.5

0 H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l

C

ontig

64

Tc00

.104

7053

5040

71.3

0 H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l PF

0050

1 A

MP-

bind

ing

enzy

me

4.00

E-07

Con

tig74

Tc

00.1

0470

5350

9455

.30

Hyp

othe

tical

pro

tein

, con

serv

ed

TEN

S056

8 T.

cru

zi e

pim

astig

ote

N

ull

no

rmal

ized

cD

NA

libr

ary

T. c

ruzi

cDN

A c

lone

568

5',

mR

NA

sequ

ence

Con

tig81

Tc

00.1

0470

5351

0329

.140

H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l

C

ontig

96

Tc00

.104

7053

5077

15.2

0 H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l

C

ontig

107

Tc00

.104

7053

5101

87.2

10

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

PF04

515

Prot

ein

of u

nkno

wn

1.3e

-50

func

tion,

DU

F580

Con

tig10

8 Tc

00.1

0470

5351

1283

.240

H

ypot

hetic

al p

rote

in, c

onse

rved

TE

NU

0619

T. c

ruzi

epi

mas

tigot

e

Nul

l

norm

aliz

ed c

DN

A li

brar

y T.

cru

zi

cD

NA

clo

ne 3

c1 3

', m

RN

A se

quen

ceC

ontig

116

Tc00

.104

7053

5064

81.3

0 H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l

C

ontig

9 Tc

00.1

0470

5350

6591

.50

Hyp

othe

tical

pro

tein

, N

ull

Nul

l

co

nser

ved

(pse

udog

ene)

Con

tig57

Tc

00.1

0470

5350

8367

.50

Hyp

othe

tical

pro

tein

, TE

NU

1365

T. c

ruzi

epi

mas

tigot

e

Nul

l

co

nser

ved

(pse

udog

ene)

no

rmal

ized

cD

NA

libr

ary

T. c

ruzi

cDN

A c

lone

21e

3 3'

, mR

NA

sequ

ence

Con

tig37

Tc

00.1

0470

5339

9389

.10

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

Con

tig77

Tc

00.1

0470

5350

7083

.109

H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l

Supp

lem

enta

ry M

ater

ial S

2. P

fam

- O

RES

TES

cont

igs.

1625



Que

ry

Subj

ect

Ann

otat

ion

EST

mat

ch

Prot

eom

e m

atch

pf

am_a

cc

pfam

_id

pfam

e-v

alue

TCA

006-

IQ22

5C_B

03_.

B_0

3.ab

1 Tc

00.1

0470

5350

4277

.30

Hyp

othe

tical

pro

tein

N

ull

Nul

l

TC

A00

6-IQ

225C

_C03

_.B

_05.

ab1

Tc00

.104

7053

5043

93.1

0 H

ypot

hetic

al p

rote

in

TEN

G05

14 T

. cru

zi e

pim

astig

ote

N

ull

no

rmal

ised

cD

NA

libr

ary

T. c

ruzi

cDN

A c

lone

n89

4.r 5

',

mR

NA

sequ

ence

TC

A00

6-IQ

225C

_C04

_.B

_06.

ab1

Tc00

.104

7053

5067

97.2

0 H

ypot

hetic

al p

rote

in

Nul

l N

ull

TCA

006-

IQ22

5C_D

04_.

B_0

8.ab

1 Tc

00.1

0470

5350

8811

.55

Hyp

othe

tical

pro

tein

am

astc

-122

5 Tc

AM

T. c

ruzi

N

ull

cD

NA

clo

ne 9

G8

5',

m

RN

A se

quen

ce

TCA

006-

IQ22

5C_D

08_.

B_0

8.ab

1 Tc

00.1

0470

5350

7641

.250

H

ypot

hetic

al p

rote

in

Nul

l N

ull

PF04

749

PLA

C8

fam

ily

6.30

E-06

TCA

006-

IQ22

5C_E

04_.

B_1

0.ab

1 Tc

00.1

0470

5350

4277

.30

Hyp

othe

tical

pro

tein

SG

-4-6

T. c

ruzi

diff

eren

tial d

ispl

ay

Nul

l

cDN

A li

brar

y T.

cru

zi c

DN

A,

m

RN

A se

quen

ce

TCA

006-

IQ22

5E_A

03_.

B_0

1.ab

1 Tc

00.1

0470

5350

7953

.130

H

ypot

hetic

al p

rote

in

TEN

U40

24 T

. cru

zi e

pim

astig

ote

N

ull

no

rmal

ized

cD

NA

libr

ary

T. c

ruzi

cDN

A c

lone

1l2

3',

m

RN

A se

quen

ceTC

A00

6-IQ

225E

_A06

_.B

_02.

ab1

Tc00

.104

7053

5082

13.3

0 H

ypot

hetic

al p

rote

in

Nul

l N

ull

TCA

006-

IQ22

5E_A

10_.

B_0

2.ab

1 Tc

00.1

0470

5350

9433

.30

Hyp

othe

tical

pro

tein

N

ull

Nul

l

TC

A00

6-IQ

225G

_C10

_.b_

06.a

b1

Tc00

.104

7053

5118

25.1

10

Hyp

othe

tical

pro

tein

TE

NF0

697

T. c

ruzi

epi

mas

tigot

e

Nul

l

norm

aliz

ed c

DN

A li

brar

y T.

cru

zi

cD

NA

clo

ne 6

97 5

',

mR

NA

sequ

ence

TC

A00

7-IQ

231B

_A07

_.B

_01.

ab1

Tc00

.104

7053

5088

11.1

0 H

ypot

hetic

al p

rote

in

Nul

l N

ull

TCA

008-

IQ22

9B_F

03_.

B_1

1.ab

1 Tc

00.1

0470

5350

4153

.370

H

ypot

hetic

al p

rote

in

Nul

l N

ull

TCA

009-

IQ23

0B_E

09_.

B_0

9.ab

1 Tc

00.1

0470

5351

1873

.5

Hyp

othe

tical

pro

tein

N

ull

Nul

l

TC

A00

9-IQ

230C

_B04

_.B

_04.

ab1

Tc00

.104

7053

5104

07.7

0 H

ypot

hetic

al p

rote

in

Nul

l N

ull

PF00

787

PX d

omai

n 2.

9e-0

6TC

A00

9-IQ

230E

_A04

_.B

_02.

ab1

Tc00

.104

7053

5088

69.1

0 H

ypot

hetic

al p

rote

in

TEN

U34

57 T

. cru

zi e

pim

astig

ote

N

ull

no

rmal

ized

cD

NA

libr

ary

T. c

ruzi

cDN

A c

lone

29g

24 5

’ sim

ilar t

o

T. c

ruzi

85

kD su

rfac

e an

tigen

(gp8

5) g

b|M

6483

6|TR

B85

KD

,

mR

NA

sequ

ence

TC

A00

9-IQ

230E

_C04

_.B

_06.

ab1

Tc00

.104

7053

5063

67.1

70

Hyp

othe

tical

pro

tein

N

ull

Nul

l

TC

A00

9-IQ

230E

_H01

_.B

_15.

ab1

Tc00

.104

7053

5074

29.6

0 H

ypot

hetic

al p

rote

in

Nul

l N

ull

TCA

236-

IQ00

1_C

07_.

B_0

5.ab

1 Tc

00.1

0470

5350

6503

.53

Hyp

othe

tical

pro

tein

N

ull

Nul

l

TC

A23

6-IQ

001_

D08

_.B

_08.

ab1

Tc00

.104

7053

5104

99.2

0 H

ypot

hetic

al p

rote

in

Nul

l N

ull

Supp

lem

enta

ry M

ater

ial S

2. P

fam

- O

RES

TES

sing

leto

ns.

Con

tinue

d on

nex

t pag

e

1626


C. Martins et al.

Que

ry

Subj

ect

Ann

otat

ion

EST

mat

ch

Prot

eom

e m

atch

pf

am_a

cc

pfam

_id

pfam

e-v

alue

TCE0

06-I

Q22

5A_C

07_.

B_0

5.ab

1 Tc

00.1

0470

5350

6825

.190

H

ypot

hetic

al p

rote

in

TEN

U28

35 T

. cru

zi e

pim

astig

ote

N

ull

no

rmal

ized

cD

NA

libr

ary

T. c

ruzi

cDN

A c

lone

27d

2 5'

,

mR

NA

sequ

ence

TCA

009-

IQ23

0E_H

02_.

B_1

6.ab

1 Tc

00.1

0470

5350

9473

.10

Hyp

othe

tical

pro

tein

(pse

udog

ene)

N

ull

Nul

l

TC

A00

6-IQ

225C

_A07

_.B

_01.

ab1

Tc00

.104

7053

5065

31.4

0 H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l PF

0027

1/PF

0440

8 H

elic

ase

cons

erve

d 2.

3e-0

8/2.

2e-0

8

C

-term

inal

dom

ain/

Hel

icas

e as

soci

ated

do

mai

n (H

A2)

TC

A00

6-IQ

225C

_A12

_.B

_02.

ab1

Tc00

.104

7053

5101

23.1

0 H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l

TC

A00

6-IQ

225C

_B08

_.B

_04.

ab1

Tc00

.104

7053

5075

83.6

0 H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l

TC

A00

6-IQ

225C

_B09

_.B

_03.

ab1

Tc00

.104

7053

5079

41.1

00

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

TCA

006-

IQ22

5C_C

01_.

B_0

5.ab

1 Tc

00.1

0470

5351

0101

.340

H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l

TC

A00

6-IQ

225C

_C05

_.B

_05.

ab1

Tc00

.104

7053

4040

01.2

0 H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l

TC

A00

6-IQ

225C

_C06

_.B

_06.

ab1

Tc00

.104

7053

5062

03.4

0 H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l

TC

A00

6-IQ

225C

_D01

_.B

_07.

ab1

Tc00

.104

7053

5108

77.1

90

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

TCA

006-

IQ22

5C_D

10_.

B_0

8.ab

1 Tc

00.1

0470

5350

6401

.240

H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l

TC

A00

6-IQ

225C

_E01

_.B

_09.

ab1

Tc00

.104

7053

5105

65.1

79

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

TCA

006-

IQ22

5C_E

08_.

B_1

0.ab

1 Tc

00.1

0470

5350

8781

.70

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

PF01

529

DH

HC

zin

c

4.40

E-29

finge

r dom

ain

TCA

006-

IQ22

5C_G

02_.

B_1

4.ab

1 Tc

00.1

0470

5350

4929

.5

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

PF00

642

Zinc

fing

er

5.60

E-08

C-x

8-C

-x5-

C-x

3-H

ty

pe (a

nd si

mila

r)TC

A00

6-IQ

225C

_G05

_.B

_13.

ab1

Tc00

.104

7053

5069

49.2

0 H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

435_

Met

a.ep

i

TC

A00

6-IQ

225C

_G06

_.B

_14.

ab1

Tc00

.104

7053

5111

33.3

0 H

ypot

hetic

al p

rote

in, c

onse

rved

TE

NU

0543

T. c

ruzi

epi

mas

tigot

e

Nul

l

norm

aliz

ed c

DN

A li

brar

y T.

cru

zi

cD

NA

clo

ne 8

h4 3

’,

mR

NA

sequ

ence

TC

A00

6-IQ

225C

_H02

_.B

_16.

ab1

Tc00

.104

7053

5097

75.3

0 H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l

TC

A00

6-IQ

225C

_H05

_.B

_15.

ab1

Tc00

.104

7053

5082

77.3

80

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

TCA

006-

IQ22

5E_A

04_.

B_0

2.ab

1 Tc

00.1

0470

5350

3697

.60

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

TCA

006-

IQ22

5E_A

09_.

B_0

1.ab

1 Tc

00.1

0470

5350

8949

.10

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

TCA

006-

IQ22

5E_B

02_.

B_0

4.ab

1 Tc

00.1

0470

5351

0101

.340

H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l

TC

A00

6-IQ

225E

_C09

_.B

_05.

ab1

Tc00

.104

7053

5063

21.2

70

Hyp

othe

tical

pro

tein

, con

serv

ed

TEN

U22

75 T

. cru

zi e

pim

astig

ote

N

ull

PF00

097

Zinc

fing

er,

3.40

E-06

no

rmal

ized

cD

NA

libr

ary

T. c

ruzi

C

3HC

4 ty

pe

cD

NA

clo

ne 1

0k16

3’,

(RIN

G fi

nger

)

mR

NA

sequ

ence

Supp

lem

enta

ry M

ater

ial S

2. C

ontin

ued.

Con

tinue

d on

nex

t pag

e

1627



Que

ry

Subj

ect

Ann

otat

ion

EST

mat

ch

Prot

eom

e m

atch

pf

am_a

cc

pfam

_id

pfam

e-v

alue

TCA

006-

IQ22

5E_E

08_.

B_1

0.ab

1 Tc

00.1

0470

5350

8173

.264

H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l

TC

A00

6-IQ

225E

_F07

_.B

_11.

ab1

Tc00

.104

7053

5087

19.9

H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l

TC

A00

6-IQ

225E

_F11

_.B

_11.

ab1

Tc00

.104

7053

5078

09.6

0 H

ypot

hetic

al p

rote

in, c

onse

rved

TE

NS2

289

T. c

ruzi

epi

mas

tigot

e

norm

aliz

ed c

DN

A li

brar

y T.

cru

zi

cD

NA

clo

ne 2

289

5',

m

RN

A se

quen

ce

Nul

l

TC

A00

6-IQ

225E

_G03

_.B

_13.

ab1

Tc00

.104

7053

5108

57.1

0 H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l PF

0075

5 C

holin

e/C

arni

tine

2.

80E-

10

o-

acyl

trans

fera

seTC

A00

6-IQ

225E

_G04

_.B

_14.

ab1

Tc00

.104

7053

5091

71.7

0 H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l

TC

A00

6-IQ

225E

_H01

_.B

_15.

ab1

Tc00

.104

7053

4539

17.9

H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

33_T

rypo

.met

a

TC

A00

6-IQ

225E

_H02

_.B

_16.

ab1

Tc00

.104

7053

5067

95.9

0 H

ypot

hetic

al p

rote

in, c

onse

rved

TE

NU

0078

T. c

ruzi

epi

mas

tigot

e

Nul

l

norm

aliz

ed c

DN

A li

brar

y T.

cru

zi

cD

NA

clo

ne 5

e11

3',

m

RN

A se

quen

ceTC

A00

6-IQ

225E

_H06

_.B

_16.

ab1

Tc00

.104

7053

5038

93.1

70

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

TCA

006-

IQ22

5E_H

07_.

B_1

5.ab

1 Tc

00.1

0470

5350

9451

.70

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

TCA

006-

IQ22

5F_A

04_.

b_02

.ab1

Tc

00.1

0470

5351

0101

.340

H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l

TC

A00

6-IQ

225F

_C07

_.b_

05.a

b1

Tc00

.104

7053

5101

01.3

40

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

TCA

006-

IQ22

5F_D

03_.

b_07

.ab1

Tc

00.1

0470

5350

9641

.60

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

TCA

006-

IQ22

5F_G

01_.

b_13

.ab1

Tc

00.1

0470

5350

6797

.10

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

PF00

622

SPRY

dom

ain

2.20

E-09

TCA

006-

IQ22

5F_G

08_.

b_14

.ab1

Tc

00.1

0470

5350

4797

.144

H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l

TC

A00

6-IQ

225F

_H07

_.b_

15.a

b1

Tc00

.104

7053

5044

27.3

0 H

ypot

hetic

al p

rote

in, c

onse

rved

TE

NU

1196

T. c

ruzi

epi

mas

tigot

e

Nul

l

norm

aliz

ed c

DN

A li

brar

y T.

cru

zi

cD

NA

clo

ne 2

0i24

3’,

m

RN

A se

quen

ce

TCA

006-

IQ22

5G_A

01_.

b_01

.ab1

Tc

00.1

0470

5351

0423

.40

Hyp

othe

tical

pro

tein

, con

serv

ed

amas

tc-1

111

TcA

M T

. cru

zi

Nul

l

cDN

A c

lone

8E1

1 5’

,

mR

NA

sequ

ence

TC

A00

6-IQ

225G

_A07

_.b_

01.a

b1

Tc00

.104

7053

5064

39.1

8 H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l

TC

A00

6-IQ

225G

_A08

_.b_

02.a

b1

Tc00

.104

7053

5064

01.2

90

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

TCA

006-

IQ22

5G_C

06_.

b_06

.ab1

Tc

00.1

0470

5351

0773

.9

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

TCA

006-

IQ22

5G_C

07_.

b_05

.ab1

Tc

00.1

0470

5341

4243

.20

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

TCA

006-

IQ22

5G_C

11_.

b_05

.ab1

Tc

00.1

0470

5350

9169

.10

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

TCA

006-

IQ22

5G_D

06_.

b_08

.ab1

Tc

00.1

0470

5350

6305

.5

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

TCA

006-

IQ22

5G_E

02_.

b_10

.ab1

Tc

00.1

0470

5350

9589

.50

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

PF07

202

T-co

mpl

ex p

rote

in

3.90

E-31

10 C

-term

inus

TCA

006-

IQ22

5G_E

05_.

b_09

.ab1

Tc

00.1

0470

5350

7963

.30

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

Supp

lem

enta

ry M

ater

ial S

2. C

ontin

ued.

Con

tinue

d on

nex

t pag

e

1628


C. Martins et al.

Que

ry

Subj

ect

Ann

otat

ion

EST

mat

ch

Prot

eom

e m

atch

pf

am_a

cc

pfam

_id

pfam

e-v

alue

TCA

006-

IQ22

5G_F

08_.

b_12

.ab1

Tc

00.1

0470

5350

8731

.40

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

TCA

006-

IQ22

5G_F

09_.

b_11

.ab1

Tc

00.1

0470

5351

1001

.80

Hyp

othe

tical

pro

tein

, con

serv

ed

amas

tc-1

56 T

cAM

T. c

ruzi

N

ull

cD

NA

clo

ne 1

1H1

5',

m

RN

A se

quen

ce

TCA

006-

IQ22

5G_F

12_.

b_12

.ab1

Tc

00.1

0470

5350

3833

.50

Hyp

othe

tical

pro

tein

, con

serv

ed

TEN

G01

26 T

. cru

zi e

pim

astig

ote

N

ull

no

rmal

ised

cD

NA

libr

ary

T. c

ruzi

cDN

A c

lone

n12

6.r 5

',

mR

NA

sequ

ence

TC

A00

6-IQ

225G

_H04

_.b_

16.a

b1

Tc00

.104

7053

5061

55.8

0 H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l

TC

A00

7-IQ

231A

_A12

_.B

_02.

ab1

Tc00

.104

7053

5108

77.1

60

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

TCA

007-

IQ23

1A_B

08_.

B_0

4.ab

1 Tc

00.1

0470

5351

1115

.10

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

PF02

138

Bei

ge/B

EAC

H

3.10

E-10

7

do

mai

n TC

A00

7-IQ

231A

_F06

_.B

_12.

ab1

Tc00

.104

7053

5110

37.4

0 H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l

TCA

007-

IQ23

1A_H

07_.

B_1

5.ab

1 Tc

00.1

0470

5350

5789

.20

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

TCA

007-

IQ23

1A_H

10_.

B_1

6.ab

1 Tc

00.1

0470

5351

0311

.40

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

TCA

007-

IQ23

1B_C

02_.

B_0

6.ab

1 Tc

00.1

0470

5351

0297

.110

H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l PF

0002

7/

cycl

ic n

ucle

otid

e-

9.1e

-17

/ 2.6

e-06

PF

0002

7 bi

ndin

g do

mai

n/

C

2 do

mai

n TC

A00

7-IQ

231B

_F11

_.B

_11.

ab1

Tc00

.104

7053

5113

65.9

0 H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l

TC

A00

7-IQ

231B

_H10

_.B

_16.

ab1

Tc00

.104

7053

5081

11.4

0 H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l PF

0063

2 H

ECT-

dom

ain

5.

10E-

20

(u

biqu

itin-

trans

fera

se)

TCA

008-

IQ22

9A_A

06_.

B_0

2.ab

1 Tc

00.1

0470

5350

8811

.30

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

TCA

008-

IQ22

9A_B

06_.

B_0

4.ab

1 Tc

00.1

0470

5350

6247

.160

H

ypot

hetic

al p

rote

in, c

onse

rved

TE

NU

3645

T. c

ruzi

epi

mas

tigot

e

Nul

l

norm

aliz

ed c

DN

A li

brar

y T.

cru

zi

cD

NA

clo

ne 2

9l21

5',

m

RN

A se

quen

ceTC

A00

8-IQ

229A

_B12

_.B

_04.

ab1

Tc00

.104

7053

5115

33.1

0 H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l

TC

A00

8-IQ

229A

_C11

_.B

_05.

ab1

Tc00

.104

7053

5063

21.2

80

Hyp

othe

tical

pro

tein

, con

serv

ed

TEN

U38

97 T

. cru

zi e

pim

astig

ote

N

ull

no

rmal

ized

cD

NA

libr

ary

T. c

ruzi

cDN

A c

lone

42g

4 5’

,

mR

NA

sequ

ence

TC

A00

8-IQ

229A

_F08

_.B

_12.

ab1

Tc00

.104

7053

5110

71.2

02

Hyp

othe

tical

pro

tein

, con

serv

ed

TcTR

-113

3 Tc

TR T

. cru

zi

Nul

l

cDN

A c

lone

09k

20 5

’,

mR

NA

sequ

ence

TC

A00

8-IQ

229B

_A09

_.B

_01.

ab1

Tc00

.104

7053

5065

59.3

60

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

Con

tinue

d on

nex

t pag

e

Supp

lem

enta

ry M

ater

ial S

2. C

ontin

ued.

1629



Que

ry

Subj

ect

Ann

otat

ion

EST

mat

ch

Prot

eom

e m

atch

pf

am_a

cc

pfam

_id

pfam

e-v

alue

TCA

008-

IQ22

9B_C

09_.

B_0

5.ab

1 Tc

00.1

0470

5351

1467

.30

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

PF03

031

NLI

inte

ract

ing

2.

30E-

10

fa

ctor

-like

phos

phat

ase

TCA

008-

IQ22

9B_C

10_.

B_0

6.ab

1 Tc

00.1

0470

5350

6825

.219

H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l

TC

A00

8-IQ

229B

_F01

_.B

_11.

ab1

Tc00

.104

7053

5114

27.1

9 H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l

TC

A00

8-IQ

229B

_F11

_.B

_11.

ab1

Tc00

.104

7053

5067

29.9

0 H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l PF

0498

1 N

MD

3 fa

mily

3.

10E-

89TC

A00

8-IQ

229B

_G06

_.B

_14.

ab1

Tc00

.104

7053

5089

53.1

0 H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l PF

0769

0 tra

nspo

rter,

maj

or

9.70

E-17

faci

litat

or fa

mily

TCA

009-

IQ23

0A_A

09_.

B_0

1.ab

1 Tc

00.1

0470

5350

8739

.40

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

TCA

009-

IQ23

0A_D

06_.

B_0

8.ab

1 Tc

00.1

0470

5350

4047

.50

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

TCA

009-

IQ23

0A_D

08_.

B_0

8.ab

1 Tc

00.1

0470

5350

7817

.60

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

TCA

009-

IQ23

0B_C

09_.

B_0

5.ab

1 Tc

00.1

0470

5350

7483

.80

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

PF05

889

Solu

ble

liver

ant

igen

/ 3.

50E-

96

liv

er p

ancr

eas a

ntig

en

(SLA

/LP

auto

antig

en)

TCA

009-

IQ23

0B_D

05_.

B_0

7.ab

1 Tc

00.1

0470

5350

3697

.70

Hyp

othe

tical

pro

tein

, con

serv

ed

TEN

Q08

90 T

. cru

zi e

pim

astig

ote

18

4_A

ma.

met

a

norm

aliz

ed c

DN

A li

brar

y T.

cru

zi

cD

NA

, mR

NA

sequ

ence

TC

A00

9-IQ

230B

_G02

_.B

_14.

ab1

Tc00

.104

7053

5083

21.4

0 H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l

TC

A00

9-IQ

230C

_D08

_.B

_08.

ab1

Tc00

.104

7053

5092

05.1

20

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

PF02

129

/ X

-Pro

dip

eptid

yl-

4E-8

6 / 1

.5e-

40

PF08

530

pept

idas

e

(S

15 fa

mily

) /

X-P

ro d

ipep

tidyl

-

pe

ptid

ase

C

-term

inal

non

-

ca

taly

tic d

omai

nTC

A00

9-IQ

230C

_E04

_.B

_10.

ab1

Tc00

.104

7053

5115

85.1

0 H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l

TC

A00

9-IQ

230D

_F11

_.B

_11.

ab1

Tc00

.104

7053

5101

21.9

0 H

ypot

hetic

al p

rote

in, c

onse

rved

TE

NU

3409

T. c

ruzi

epi

mas

tigot

e

Nul

l

norm

aliz

ed c

DN

A li

brar

y T.

cru

zi

cD

NA

clo

ne 2

9b3

5',

m

RN

A se

quen

ce

TCA

009-

IQ23

0E_B

12_.

B_0

4.ab

1 Tc

00.1

0470

5351

1657

.30

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

TCA

009-

IQ23

0E_C

12_.

B_0

6.ab

1 Tc

00.1

0470

5351

1071

.202

H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l

TC

A00

9-IQ

230E

_F02

_.B

_12.

ab1

Tc00

.104

7053

5061

77.5

0 H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l

TC

A00

9-IQ

230E

_G03

_.B

_13.

ab1

Tc00

.104

7053

5105

65.1

79

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

TCA

009-

IQ23

0E_G

12_.

B_1

4.ab

1 Tc

00.1

0470

5350

6579

.40

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

PF07

690

Tran

spor

ter,

maj

or

2.60

E-07

faci

litat

or fa

mily

TCA

236-

IQ00

1_B

11_.

B_0

3.ab

1 Tc

00.1

0470

5350

4153

.270

H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l

Supp

lem

enta

ry M

ater

ial S

2. C

ontin

ued.

Con

tinue

d on

nex

t pag

e

1630


C. Martins et al.

Que

ry

Subj

ect

Ann

otat

ion

EST

mat

ch

Prot

eom

e m

atch

pf

am_a

cc

pfam

_id

pfam

e-v

alue

TCA

236-

IQ00

1_D

05_.

B_0

7.ab

1 Tc

00.1

0470

5350

7641

.160

H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l PF

0150

5 M

ajor

Vau

lt

9.60

E-06

Prot

ein

repe

atTC

A23

6-IQ

001_

F11_

.B_1

1.ab

1 Tc

00.1

0470

5350

4643

.20

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

PF01

479

S4 d

omai

n 5.

60E-

06TC

A23

6-IQ

001_

G06

_.B

_14.

ab1

Tc00

.104

7053

5065

05.3

0 H

ypot

hetic

al p

rote

in, c

onse

rved

TE

NG

0388

T. c

ruzi

epi

mas

tigot

e

Nul

l

norm

alis

ed c

DN

A li

brar

y T.

cru

zi

cD

NA

clo

ne n

731.

r 5',

m

RN

A se

quen

ce

TCA

236-

IQ00

1_G

11_.

B_1

3.ab

1 Tc

00.1

0470

5350

7979

.50

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

TCA

236-

IQ00

1_H

01_.

B_1

5.ab

1 Tc

00.1

0470

5350

5555

.40

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

TCA

236-

IQ00

1_H

05_.

B_1

5.ab

1 Tc

00.1

0470

5351

0055

.150

H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l

TC

A23

6-IQ

001_

H07

_.B

_15.

ab1

Tc00

.104

7053

5062

65.6

0 H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l

TC

E006

-IQ

225A

_C10

_.B

_06.

ab1

Tc00

.104

7053

5041

37.4

0 H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l

TC

E006

-IQ

225A

_E06

_.B

_10.

ab1

Tc00

.104

7053

5083

47.3

0 H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l

TC

E006

-IQ

225A

_F03

_.B

_11.

ab1

Tc00

.104

7053

5098

05.1

00

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

TCE0

06-I

Q22

5A_G

03_.

B_1

3.ab

1 Tc

00.1

0470

5351

1435

.10

Hyp

othe

tical

pro

tein

, con

serv

ed

Nul

l N

ull

TCE0

06-I

Q22

5B_E

01_.

B_0

9.ab

1 Tc

00.1

0470

5351

0055

.100

H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l

TC

E006

-IQ

225B

_F07

_.B

_11.

ab1

Tc00

.104

7053

5092

47.3

0 H

ypot

hetic

al p

rote

in, c

onse

rved

N

ull

Nul

l PF

0405

4 CC

R4-N

ot c

ompl

ex

8.70

E-48

com

pone

nt, N

ot1

TCA

006-

IQ22

5C_E

06_.

B_1

0.ab

1 Tc

00.1

0470

5351

0533

.210

H

ypot

hetic

al p

rote

in, c

onse

rved

(pse

udog

ene)

N

ull

Nul

l

TC

A00

6-IQ

225G

_G07

_.b_

13.a

b1

Tc00

.104

7053

5041

31.1

0 H

ypot

hetic

al p

rote

in, c

onse

rved

(pse

udog

ene)

N

ull

Nul

l

TC

A00

8-IQ

229B

_G01

_.B

_13.

ab1

Tc00

.104

7053

5098

91.7

0 H

ypot

hetic

al p

rote

in, c

onse

rved

(pse

udog

ene)

N

ull

Nul

l

TC

A00

9-IQ

230B

_E10

_.B

_10.

ab1

Tc00

.104

7053

5106

45.4

0 H

ypot

hetic

al p

rote

in, c

onse

rved

(pse

udog

ene)

N

ull

Nul

l

Supp

lem

enta

ry M

ater

ial S

2. C

ontin

ued.

identification of genes encoding hypothetical proteins in ... · these genes, we generated 1161...

Documents